



Annual and Financial Report 2025



Contents

1. Annual Report	3
Preface	4
A few words from our Chairperson	4
A few words from the Chairperson of the European Working Group of People with Dementia	6
A few words from the Chairperson of the European Dementia Carers Working Group	7
Executive Summary	8
Introduction	13
AE Core Activities	13
Objective 1: Providing a voice to people affected by dementia	13
Objective 2: Making dementia a European priority	17
Objective 3: Changing perceptions and combating stigma	21
Objective 4: Raising awareness of brain health and prevention	22
Objective 5: Strengthening the European dementia movement	24
Objective 6: Supporting dementia research	26
Other activities and projects	29
Involvement in EU projects	29
Support of European research activities	36
Corporate affairs	38
Organisational changes	43
Annex 1: Meetings and conferences	44
Meetings organised by Alzheimer Europe (AE) in the framework of the 2025 Operating Grant	44
Other meetings organised by Alzheimer Europe	45
EU project meetings	45
Other meetings	46
Annex 2: Scientific publications in 2025	50
2. Financial Report	51
A few words from our Honorary Treasurer	52
Report of the Réviseur d'entreprises agréé	55
Balance sheet as of December 31, 2025	57
Profit and loss account – Year ended December 31, 2025	58
Notes to the Annual Accounts as at December 31, 2025	59
Breakdown of income	65
Our sponsors and supporters	67
3. Alzheimer Europe Board and staff	68



Annual Report

Preface

A few words from our Chairperson



Maria do Rosário Zincke dos Reis

It is, as always, a great pleasure for me to write this preface for Alzheimer Europe's Annual Report. 2025 was another busy and exciting year and members of the staff, Board, and working groups should all be immensely proud of their hard work and achievements.

One of the stand-out highlights for me was our Annual Conference which took place in Bologna (Italy) under the banner “Connecting science and communities: The future of dementia care” and brought together a record number of over 1,500 delegates. It was a huge honour, at the Opening Ceremony, to receive the medal of the President of the Republic, on behalf of the conference. This medal is a token of appreciation from the Italian President and was awarded to our event for its value. It was also a great honour to hear from both Professor Orazio Schillaci, Italian Minister of Health, and Senator Beatrice Lorenzin, at our conference.

The conference attracted people from all over Europe and beyond, with 48 countries represented, and more than 800 presenters on the agenda, each sharing their research, knowledge and experience in an atmosphere of genuine collaboration. The programme was truly diverse and, as I attended sessions and made my way around the venue, I felt a real sense of joy and satisfaction to see people with dementia and carers networking with health-care professionals, academics, researchers, representatives of Alzheimer's associations, policymakers and industry representatives.

Something that really sets our conference apart from others in the dementia field is the contributions made by people with lived experience. People with dementia and carers were involved in the planning process and preparatory stages and members of our European Working Group of People with Dementia (EWGPWD) and the European Dementia Carers Working Group (EDCWG) planned and organised the first plenary session of the conference. The plenary, which was moderated by Trevor Salomon, Chairperson of the EDCWG, was called “Dementia as a European and national policy and research priority – as seen by people with dementia and their carers” and the speakers were Kevin Quaid, Chairperson of the EWGPWD, Annick Germeyns, member of the EDCWG, Gerda Van Tongerloo, Vice-Chairperson of the EWGPWD, and Rosslyn Vella, Vice-Chairperson of the EDCWG. I warmly congratulate them

on this fantastic session. Congratulations, also, to the wider Alzheimer Europe team on such a successful event. I am looking forward to our 2026 conference in Dublin this October and hope to see you there!

Alzheimer Europe is particularly grateful to the European Union's Citizens, Equality, Rights and Values (CERV) programme and its support for disability organisations which allows us to fully integrate people with dementia and carers into our activities and to campaign for their inclusion as citizens in society. The Alzheimer Europe Foundation, of which I am proud to be the Vice-Chairperson, is another vital support for our working groups, providing funding to allow them to hold meetings prior to our conferences, as well as funding accommodation for people with dementia and carers during the event.

I am constantly impressed by the contributions that the members of the EWGPWD and EDCWG make to our work. They ensure that we always integrate the views and opinions of people with lived experience in our ever more varied activities and, together with our fantastic Research and Public Involvement teams, they make hugely valuable contributions to our EU-funded project portfolio, with researchers greatly appreciating the input and advice they provide, through their work in focus groups and consultations. In 2025, we partnered in multiple projects funded by the European research programmes Horizon 2020, Horizon Europe, the Innovative Health Initiative (IHI) and the Innovative Medicines Initiative (IMI), as well as participating in two JPND (Joint Programme Neurodegenerative Diseases Research) projects and one ERA PerMed project funded by the Fonds National pour la Recherche (FNR) in Luxembourg. In each of these projects, Alzheimer Europe ensured that the views of people with dementia, carers and Alzheimer's associations were included, contributed to the discussion of the ethical issues and policy challenges raised, and supported or led the communication, dissemination and stakeholder engagement activities.

As well as their dedication to informing research, both the EWGPWD and the EDCWG contributed to publications such as our Dementia in Europe Yearbook 2025, which focused on programmes and resources relating to transport and access to cultural life, recreation, leisure and sport. Group members also wrote articles for our monthly newsletters and Dementia in Europe policy magazines.

Our policy work relies on vital support from two groups of dedicated policy-makers with an interest in ensuring that dementia is a European priority: the European Alzheimer's Alliance (EAA) and the European Group of Governmental Experts on Dementia. As at the end of 2025, there were 89 MEPs from 22 Member States in the EAA and we are grateful to each and every one of them for their support, but especially to the Vice-Chairs, who regularly and actively support our work, including hosting our European Parliament lunch debates in Brussels (Belgium). They also support the work of our national member associations in their home countries. 2025 saw a seventh EAA Vice-Chair join the fold: Vladimir Prebilič MEP (Greens/EFA, Slovenia). He joined Nina Carberry MEP (EPP, Ireland), Romana Jerković MEP (S&D, Croatia), Tilly Metz MEP (Greens/EFA, Luxembourg), Sirpa Pietikäinen MEP (EPP, Finland), Hilde Vautmans MEP (Renew, Belgium) and Dainius Žalimas MEP (Renew, Lithuania).

The European Group of Governmental Experts on Dementia meets regularly to exchange information and best practices on national dementia strategies and policies, as well as European and international policy developments. It was formed in 2018 by Alzheimer Europe, the Dutch Ministry of Health, Welfare and Sport, the Italian Ministry of Health and the Scottish Government. The group, which is facilitated by Alzheimer Europe, consists of representatives from national ministries in European countries, alongside representatives from the World Health Organization (WHO), WHO Europe, the European Commission, the Organisation for Economic Cooperation and Development (OECD) and the Joint Action on Dementia and Health (JADE-Health). I am delighted that our collaboration with both of these groups has not only continued but flourished in recent years, with 2025 being no exception.

Another aspect of our work which I particularly enjoy is the Anti-Stigma Award that Alzheimer Europe organises together with the Alzheimer Europe Foundation, and for which we are hugely grateful to C2N Diagnostics, Lilly and Roche for their sponsorship. The 2025 award, aimed to give recognition to a European artist using photography or painting to address stigma and convey a positive image of dementia and people living with dementia. The winners were announced at a special award ceremony in Brussels in December, with Photographer Alex Kornhuber taking home the first-place prize for "Keepsake Chronicles", an Irish-born collaboration between the photographer, a poet (Cathy Fowley), and a nurse (Kate Irving). Second place, which I was delighted to present at the ceremony, went to Desideria Care e.V. for their open-air photo exhibition "Seeing Dementia in a New Light", and Third place was awarded to Bálint Szajki, a photographer from Hungary, for his deeply intimate photo essay, titled "In Sickness and in Health". Huge congratulations to all three winners and to the remaining six finalists, who were each awarded an "Honourable Mention". A special thank you goes to Nina Carberry MEP for hosting the award ceremony.

Alzheimer Europe continued its collaboration with the European Medicines Agency (EMA) in 2025 as an accredited patient organisation and as a full member of the EMA's Patients' and Consumers' Working Party (PCWP).

The organisation closely followed discussions on the introduction and authorisation of anti-amyloid treatments in Europe. After welcoming the recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the EMA for a marketing authorisation of lecanemab in 2024, the association noted the delays with the approval process and in March 2025, wrote to European Commissioner for Health and Animal Welfare, Olivér Várhelyi, to express grave concern about the delays. In April, we welcomed the formal approval of lecanemab by the European Commission. Regarding the approval process of donanemab, Alzheimer Europe actively supported the re-examination process at CHMP level after the initial rejection, submitted a third-party intervention in favour of a positive evaluation, and welcomed the reversal by the CHMP in July, as well as the granting of the marketing authorisation by the Commission in September.

Another hugely important piece of work completed by the team in 2025 was a new report, "The Prevalence of Dementia in Europe 2025", which provides updated figures for the number of people living with dementia both for Europe as a whole, as well as the countries within, building upon our previous work in the "Dementia in Europe Yearbook 2019". Both reports relied heavily on collaboration with experts and researchers from across Europe, who provided us with vital data, without which the publication would not have been possible.

This brings me to my final highlight of 2025: the excellent collaboration between Alzheimer Europe and our national member organisations across the European Region. None of our work would be possible without the active contributions of our members, who help us collect data for our Dementia in Europe Yearbook, contribute to our other publications such as our newsletter and magazine, support our lobbying activities, and participate in our regular Alzheimer's Association Academy sessions, Public Affairs meetings, lunch debates, and other meetings, sharing their time and experience to contribute to mutual learning around best practices in advocacy, care, policy, Public Involvement and research. It was wonderful to see 29 full members out of 36 present or represented at our Annual General Meeting (AGM) in Brussels, in June, where we were delighted to welcome five new full members, from Armenia, Lithuania, North Macedonia, Serbia and Ukraine. This brought our tally to 41 members from 36 European countries. Fantastic progress for the European Dementia Movement! In November, we held a second AGM, this time online, with 35 out of our 41 members in attendance. They unanimously adopted our new Strategic Plan for 2026-2030.

In closing, it is my privilege, as Chairperson of Alzheimer Europe, to pay special thanks to my colleagues in the Board. Each one of them plays an important role in monitoring the activities and finances of our association and in recommending and advising our staff on how to continue growing and expanding the association. It is a pleasure to chair the meetings of the Board which are not only constructive and productive, but also a real pleasure to attend, with such warm and supportive colleagues. I also want to give thanks to the outstanding staff members at Alzheimer Europe, under the leadership of Executive Director, Jean Georges. I look forward to continuing our excellent collaboration in 2026, which I am sure will be yet another very successful year.

Maria do Rosário Zincke dos Reis
Chairperson
Alzheimer Europe

A few words from the Chairperson of the European Working Group of People with Dementia



Kevin Quaid

I am so grateful to be writing these words to you, in my position as Chair of the European Working Group of People with Dementia (EWGPD). What an honour and a privilege it is for me, and I would like to think that I am doing the role justice, helping guide the group’s meetings and discussions and encouraging and motivating others to make sure the voice of people with invisible disabilities is heard and listened to! As the group’s representative on the organisation’s Board of Directors, I take that part of my role very seriously as well and am really grateful to have a seat at the table.

I have huge respect and appreciation for all my colleagues in the EWG-PWD, as well as on the Alzheimer Europe Board, and truly enjoy the time we spend together. I want to celebrate the work of the EWGPD, and the great strides we are making. As a group, we don’t content ourselves with taking a back seat and we will always keep pushing for change for ourselves and for others like us, now and in the future.

In 2025, as every year, our group did a lot of work and contributed to many aspects of Alzheimer Europe’s activities, as well as to research conducted by the projects in which they are a partner, such as AD-RIDDLE, EPND and Dorian Gray, through lots of consultations. Non-tokenistic Public Involvement is becoming more the norm in European research projects like these, which is brilliant to see, and of course as it should be! We, who have lived experience of dementia, should always have a seat at the table, as we are best placed to help researchers, pharma companies, healthcare professional and others to understand our real needs and wishes, so that they, in turn, can develop better treatments, therapies, technologies and care.

I am in awe of the work our group does, both as a collective and as individuals in our own countries, including:

- The work put into last year’s Alzheimer Europe Conference in Bologna, “Connecting science and communities: The future of dementia care”, which featured members of the group on the scientific committee reviewing and rating abstracts for the conference, presenting at the first plenary session, giving presentations at parallel sessions and presenting posters. A great experience altogether! Some of us even participated in a photography and storytelling project organised by the Ri-Scatti project and Federazione Alzheimer Italia, by taking pictures showing our experiences, feelings and emotions during the event. A slideshow was shared with the audience at the Closing Ceremony - a lovely and creative way to showcase the lived experience!
- Our contribution to the 2025 Dementia in Europe Yearbook - which focused on the topic of transport and access to cultural life, recreation, leisure and sport - by providing our experiences and views, to

highlight the importance of these areas, all of which are vital to our enjoyment of daily life, meeting the needs of people with dementia.

- The numerous articles that group members wrote for the Dementia in Europe magazine and the Alzheimer Europe newsletter.
- Our participation in Public Involvement consultations to provide insights for the “Dementia Research Participation and Data Sharing in Europe” report that was developed with funding from Gates Ventures.
- The discussion paper and guidelines that we published, about the ethical use of technology for and by people with dementia.

As a group, we may not always agree with each other, but we are all willing and able to see each other’s perspective and to give everyone the respect they deserve and the opportunity to share their thoughts and experiences. The advocacy work we do is going from strength to strength, and I am sure it will continue to do so.

The importance of respecting others’ opinions and of really listening is sometimes lost in the world of politics, especially at the moment. It is, therefore both inspiring and comforting to attend Alzheimer Europe’s policy events such as the two lunch debates organised during 2025, at the European Parliament in Brussels, where MEPs really listen to us and to each other on topics around dementia policy. It gives me hope for the future!

Some other highlights of 2025, for me personally, include addressing the European Day of Persons with Disabilities conference in Brussels on behalf of the EWGPD, and being involved in the Anti-Stigma Award committee and having the opportunity to present one of the prizes.

The final thing I want to say is just a big thank you, to Alzheimer Europe and everyone we have worked alongside this past year, for giving us the opportunity to be properly involved and to contribute to their vital work in a meaningful way.

Kevin Quaid
Chairperson
European Working Group of People with Dementia

A few words from the Chairperson of the European Dementia Carers Working Group



Trevor Salomon

I've often asked myself why it is that the bond between dementia carers is so extraordinarily strong and, to answer my own question, I perceive that this must come down to shared experience in a situation that most people outside it don't fully understand.

So even though the make-up of the European Dementia Carers Working Group (EDCWG) changed slightly during 2025, I felt our new members instantly eased into the Group because they hopefully sensed they were understood even without having to explain their personal situations in any great detail. Such a sense of empathy creates fast and deep connections, enabling newcomers to feel confident that everyone around them relates to the emotional and practical complexities that they, and each of us, face in our daily caring roles.

There is a deep emotional intensity to the work of the EDCWG. We experience a mix of compassion, frustration, grief, and dare I say it, even dark humour. When we get together – and we hugely enjoy one another's company - we know we can share such feelings safely, without fear of being judged.

2025 was another very busy year for the Group. I don't like to feel that any one activity was more important than another but for me the highlight was co-operating with our friends and colleagues from the European Working Group of People with Dementia (EWGPWD) to co-design and coproduce the opening plenary session of the Annual Conference held in Bologna in October. The session was entitled "Dementia as a European and national policy and research priority – as seen by people with dementia and their carers". Standing on stage in front of a large audience is nerve-wracking at the best of times but when you haven't done this before AND you're speaking from the heart then this is something else. This 'something else' was clearly appreciated and felt by the delegates who gave the speakers a truly deserved standing ovation.

The Group not only assisted with the assessment of submissions for the Annual Conference but also fulfilled a similar role for the much-praised Alzheimer Europe Anti-Stigma Award which recognises an outstanding

initiative aimed at combatting stigma and promoting a positive image of dementia and people living with a diagnosis.

During the course of the year the EDCWG met both in person as well as online and also co-operated with EWGPWD in a number of activities including research participation and data sharing in dementia research. We contributed jointly to an interesting consultation on saliva biomarker collection procedures and its related guidance information.

The EDCWG's activities also included contributing throughout the year to the Alzheimer Europe Newsletter and the Dementia in Europe magazine and involving ourselves in European-funded projects and research such as DORIAN GRAY, Pattern-Cog, PREDICTOM and AI4HOPE, to name but a few.

I must stress of course that the Group's members were all very active in their home countries too and it goes without saying that everyone understands that their efforts to raise awareness of dementia and the time we devote to campaigning on behalf of carers is given even though none of us will gain from our efforts. That's not the point though. We do so because we have a shared sense of purpose and want to have a positive influence on the lives of carers coming behind us: it's really that simple.

And finally it would be remiss of me not to thank our friends at Alzheimer Europe who provided us, as always, with so much support and encouragement over the past twelve months. We greatly appreciate all of you.

Trevor Salomon
Chairperson
European Dementia Carers Working Group

Executive Summary

In 2025, Alzheimer Europe:

Provided a voice to people with dementia and their carers and

- involved 18 people with dementia from 12 European countries in its European Working Group of People with Dementia (EWG-PWD) and organised two in-person and four online meetings
- involved 17 carers of people with dementia from 15 European countries in its European Dementia Carers Working Group (EDCWG) and organised two in-person and three online meetings
- co-developed a report on the ethical, social and practical implications of the use of technology by and for people with dementia
- dedicated the first plenary of its Annual Conference to a session entitled “Dementia as a European and national policy and research priority – as seen by people with dementia and their carers”, which was planned, organised, moderated and presented by members of the EWG-PWD and EDCWG
- included testimonials from people with dementia and carers in its 2025 Yearbook on transport and access to cultural life, recreation, leisure and sport
- included articles written by people with dementia and carers in its monthly e-mail newsletters and Dementia in Europe magazine
- participated with an EWG-PWD delegation in the European Day of Persons with Disabilities
- involved members of both groups in publications, meetings as well as through Public Involvement activities in its European dementia and brain health research projects.

Made dementia a European priority and

- contributed to European Commission consultations by submitting position papers and by co-developing policy statements with other European disability and health NGOs
- participated as an active member in the meetings of the Patients' and Consumers' Working Party of the European Medicines Agency



Executive members of Alzheimer Europe's Board of Directors at our 2025 AGM, Brussels (Belgium), 4 June 2025

- closely followed the discussions on the introduction and authorisation of anti-amyloid treatments in Europe and produced a statement on the re-examination of the marketing authorisation application for donanemab, which it shared with the European Medicines Agency
- updated its 2019 report on the numbers of people affected by dementia in the European Union, publishing “The Prevalence of Dementia in Europe 2025” report
- organised one in-person and two online meetings of the European Group of Governmental Experts on Dementia, bringing together representatives from 25 countries, as well as the European Commission, Organisation for Economic Co-operation and Development (OECD) and the World Health Organization (WHO)
- worked with members of the European Alzheimer's Alliance (EAA), which consists of 89 MEPs from 22 Member States of the European Union, to make dementia a European priority, including organising two European Parliament lunch debates and inviting EAA contributions to the Dementia in Europe magazine
- dedicated its 2025 Yearbook to transport and access to cultural life, recreation, leisure and sport and carried out a survey in which 33 members participated



35th Alzheimer Europe Conference, Bologna (Italy), October 2025



Five new full member associations were welcomed to Alzheimer Europe at the 2025 AGM

- monitored EU and national policy developments of interest to people with dementia and their carers and identified 41 European and 16 national policy news to include in its newsletters.

Changed perceptions and combatted stigma and

- launched the call for its fourth Anti-stigma Award, inviting European artists active in the field of painting or photography and addressing the stigma attached to dementia whilst encouraging a positive image of dementia and people living with dementia, in collaboration with the Alzheimer Europe Foundation, C2N Diagnostics, Lilly and Roche
- organised an Anti-Stigma Award ceremony and dinner, hosted by Nina Carbery MEP (Ireland) on 2 December and announced Alex Kornhuber as the winner, for “Keepsake Chronicles”, an Irish-born collaboration between the photographer, a poet (Cathy Fowley), and a nurse (Kate Irving), with second place going to Desideria Care e.V. for their open-air photo exhibition “Seeing Dementia in a New Light”, and third place to Bálint Szajki, a photographer from Hungary, for his deeply intimate photo essay, titled “In Sickness and in Health”
- participated in an online question and answer session with touchNEUROLOGY discussing how stigma affects people living with dementia and strategies to raise awareness of this topic.

Raised awareness of brain health and prevention and

- identified five phase II trials, four phase III trials and one non-drug trial to include in its Clinical Trials Watch service
- participated in a growing number of European research projects focused on brain health, risk reduction and prevention, biomarkers and novel therapies
- continued to collaborate with the European Task Force on Brain Health, co-authoring a publication that identified opportunities and challenges for the implementation of Brain Health Services from a range of different perspectives, including patient and societal perspectives
- contributed to a panel discussion on dementia prevention and risk reduction broadcast by the Luxembourg radio station RTL
- contributed to scientific publications on psychosocial interventions, biomarkers, multimodal lifestyle interventions, brain health services, physical activity, anti-amyloid therapies,



European Working Group of People with Dementia, Bologna (Italy), October 2025

palliative care, prediction models, genetic determinants, technology, informed consent and risk disclosure, Public Involvement, participation in dementia research, and precision medicine


- published a special supplement to its October edition of Dementia in Europe magazine on the topic of Brain Health, examining dementia risk reduction and prevention from a European perspective, covering primary, secondary and tertiary prevention and underlining the importance of action across the life course and across all stages of dementia.

Strengthened the European dementia movement and

- organised two in-person Public Affairs meetings and seven online Alzheimer’s Association Academy meetings with the participation of members from 34 European countries
- involved the AE Board in the monitoring of the association’s activities and finances in relation to the agreed-upon Work Plan and budget and organised two online and three in-person meetings
- organised two Annual General Meetings
 - in Brussels (Belgium) on 4 June with 29 of its 36 full members present or represented, where it welcomed five new full members and where the members approved the 2024 Annual and Financial Reports



Annual Meeting of the INTERDEM Network, Bologna (Italy), 5 October 2025



Delegates at 35th Alzheimer Europe Conference

- online on 24 November 2025, with 35 out of 41 full members present or represented where the members unanimously adopted the 2026 Work Plan and Budget and new Strategic Plan of Alzheimer Europe (2026-2030)
- continued its collaboration with the INTERDEM network of European researchers involved in psychosocial research, the European Alzheimer’s Disease Consortium and the European Academy of Neurology
- collaborated as a full member with the European Patients’ Forum and the European Disability Forum and was also accepted as a member of the European Public Health Alliance
- partnered with other organisations in the European Care Alliance, coordinated by COFACE – Families Europe to contribute to EU discussions and policy initiatives in the field of informal and professional care.

Supported dementia research and

- involved the EWGPWD and the EDCWG, as well as its online Public Involvement Pool in the Public Involvement activities of European research projects
- contributed to a research paper entitled “Informed Consent in dementia research: how Public Involvement can contribute to addressing “old” and “new” challenges”
- contributed to the communication and dissemination of research results via its established communication tools: newsletter, website and social media and covered 485 news stories in its 11 monthly e-mail newsletters which were sent to over 10,000 subscribers
- organised its 35th Annual Conference “Connecting Science and Communities: The future of dementia care” in Bologna (Italy) from 6 to 8 October with a record number of more than 1,500 delegates from 48 countries



European Group of Governmental Experts on Dementia, Bologna (Italy), 5 October 2025

- collaborated with the Alzheimer Europe Foundation which provided bursaries for people with dementia and early-stage researchers to participate in the conference and which funded the meeting costs, as well as the travel and accommodation costs of the member of the EWGPWD and EDCWG attending the conference.

Carried out the following project-related activities:

- Continued its involvement in a number of EU-funded projects by representing the views of people with dementia and their carers in the research consortium, by contributing to the ethical discussions and by supporting the communication and dissemination activities towards a non-scientific audience with the following projects
 - ADIS (Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances)
 - AD-RIDDLE (Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement)
 - AI-MIND (Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment)
 - AI4Hope (Artificial intelligence-based health, optimism, purpose and endurance in palliative care for dementia)

- eBRAIN-Health (Actionable Multilevel Health Data)
- EPND (European Platform for Neurodegenerative Diseases)
- LETHE (A personalized prediction and intervention model for early detection and reduction of risk factors causing dementia, based on explainable AI and distributed Machine Learning)
- Multi-MeMo (Shorter- and longer-term mechanisms of multimodal interventions to prevent dementia)
- Pattern-Cog (Personalized aging pattern for early risk detection and prevention of cognitive impairment and dementia in cognitively healthy individuals)
- PREDICTOM (Prediction of Alzheimer’s disease using an AI driven screening platform)
- PROMINENT (Precision medicine platform in neurodegenerative disease).
- Started its collaboration with
 - DORIAN GRAY (Devising a personalised risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes)
 - FluidX-AD (A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer’s Disease)
 - PREDICT-FTD (Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification).



Winners and honourable mentions of the 2025 Anti-Stigma Award, Brussels (Belgium), 2 December 2025



Alzheimer Europe booth at our 35th Annual Conference



Alzheimer Europe Foundation Board meeting, 7 August 2025, Senningerberg (Luxembourg)



European Dementia Carers Working Group, Bologna (Italy), October 2025



Delegates at Alzheimer Europe's 2025 AGM

- Supported the following EU projects
 - EPAD (European Prevention of Alzheimer's Dementia)
 - HOMEDEM (CoDesigning a home with dementia)
 - PANEUCARE (Multidirectional knowledge transfer of dementia research and care between European and international regions)
 - REBALANCE (Mechanisms of focused ultrasound mediated brain cleaning coupled with enhanced mechanosensation)
 - REMOTE-AD (Remote Digital Assessment and Monitoring for Early Alzheimer's Disease)
 - TEF-Health (Testing and Experimentation Facility for Health AI and Robotics).

Carried out a number of activities thanks to the support of its corporate sponsors and other partners

- organised two European Parliament lunch debates on "Preparing for new Alzheimer's treatments in Europe" and on "The future of dementia research in Europe", with support from Sirpa Pietikäinen MEP (Finland), Romana Jerković MEP (Croatia), Hilde Vautmans MEP (Belgium) and Tilly Metz MEP (Luxembourg)
- published three editions of the Dementia in Europe magazine with interviews and contributions of EU and national policy



Applause from the audience during the 35th Alzheimer Europe Conference

makers, as well as three special supplements, one for each edition of the magazine, dedicated to the 2024 Annual Conference, the AI-Mind project and to Brain Health

- ended the year with 22 phase II trials, 12 phase III clinical trials and three non-drug trials recruiting participants in Europe included in the Clinical Trials Watch on the organisation's website
- continued a project funded by Gates Ventures exploring the attitudes and barriers of the general public towards participation in dementia and brain health research
- organised regular company round table meetings and consultations with its sponsors
- participated in meetings of the Patient think-tank of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and collaborated with PAVE, Project Alzheimer's Value in Europe.



MEPs hosting our 2025 Lunch Debates in the European Parliament (from top left to bottom right): Tilly Metz (Luxembourg), Romana Jerković (Croatia), Hilde Vautmans (Belgium), Sirpa Pietikäinen (Finland)

Introduction

The Strategic Plan of Alzheimer Europe sets out the six priorities of the organisation and highlights key aims and actions to be undertaken under each objective for the period covered by the plan (2021-2025).

As in previous editions, the Annual Report breaks down the organisation's core activities in these six key strategic areas and highlights the activities undertaken by Alzheimer Europe in support of EU pro-jects, as well as those carried out thanks to the support of its corporate sponsors and other partners.

AE Core Activities

In 2025, Alzheimer Europe received an operating grant from the European Union's Citizens, Equalities, Rights and Values (CERV) Health Programme which provided the funding for a number of the organisation's core activities included below.

Objective 1: Providing a voice to people affected by dementia

Thanks to its European Working Group of People with Dementia (EWG-PWD) and European Dementia Carers Working Group (EDCWG), Alzheimer Europe was able to ensure that the views of people affected by dementia were included in all of the organisation's projects, meetings and activities, as well as in European research projects and initiatives Alzheimer Europe contributed to.

European Working Group of People with Dementia

The EWGPWD is composed of people with a diagnosis of dementia. Members are living with different types of dementia, have different nationalities and backgrounds and are nominated by a national Alzheimer's association to join the group for a term of office of three years. The Chair of the EWGPWD sits on the Board of Alzheimer Europe and has the same rights as other Board members.



Plenary 1 speakers at the 35th Alzheimer Europe Conference (left to right): Trevor Salomon, Roslynn Vella, Gerda Van Tongerloo, Annick Germeys, Kevin Quaid

Further information about the members can be found at:

<https://www.alzheimer-europe.org/about-us/european-working-group-people-dementia/members>

From January to June 2025, the EWGPWD had the following composition:

- Chair: Kevin Quaid (Ireland)
- Vice Chair: Lieselotte Klotz (Germany)
- Members:
 - Kjell Ehn (Sweden)
 - Jan Runar Eliassen (Norway)
 - Nigel Hullah (UK – England, Wales and Northern Ireland)
 - Erla Jónsdóttir (Iceland)
 - Margaret McCallion (UK - Scotland)
 - Angela Pototschnigg (Austria)
 - Minna Kinnunen (Finland)
 - Chris Roberts (UK – England, Wales and Northern Ireland)
 - Shelagh Robinson (UK - England, Wales and Northern Ireland)
 - Věra Ryšavá (Czechia) and
 - Gerda Van Tongerloo (Netherlands)

After the (re)nomination of one third of its membership in June 2026, the EWGPWD had the following composition:

- Chair: Kevin Quaid (Ireland)
- Vice Chair: Gerda Van Tongerloo (Netherlands)
- Members:
 - Philip Angrave (UK - England, Wales and Northern Ireland)
 - Stuart Dougall (UK - Scotland)
 - Kjell Ehn (Sweden)
 - Jan Runar Eliassen (Norway)
 - Hafsteinn Fridfinnsson (Iceland)
 - Katya Genadieva (Bulgaria)
 - Jost Hamschmidt (Switzerland)
 - Erla Jónsdóttir (Iceland)
 - Lieselotte Klotz (Germany)
 - Angela Pototschnigg (Austria)
 - Shelagh Robinson (UK - England, Wales and Northern Ireland)
 - Věra Ryšavá (Czechia)
- Minna Kinnunen (Finland) stepped down in June 2025 for personal reasons.

Alzheimer Europe organised two in-person and four online meetings of the EWGPWD which were attended as follows:

Date	Number of participants	Countries represented
25, 26 and 27 March	10	8
12 June	13	11
1 July	14	12
8 September	13	11
5 and 6 October	13	11
10 December	7	7

In addition, other meetings that did not involve all members were held including:

- Regular meetings with the Executive of the EWGPWD (Chair and Vice Chair)
- Meetings in May with members who needed help with preparation and submission of abstracts for parallel sessions at the AE conference
- Meetings between May and October to prepare for a photography initiative at the annual conference

The EWGPWD also contributed to the 2025 Yearbook which focused on the topic of transport and access to cultural life, recreation, leisure and sport. As in previous years, Alzheimer Europe wanted to ensure that the voices of people with dementia and carers were reflected in this work. Whilst the Yearbook itself provides the policy and legislative context of transport and cultural life, this does not necessarily correspond to the personal priorities and experiences of people living with the condition. Members of the EWGPWD contributed to this work by providing their experiences and views, these underscore the importance of transport and cultural life, services and supports responding to the needs of people with lived experience. They also commented on draft recommendations.

The 2025 AE conference, held in Bologna, Italy, featured many members of the EWGPWD. Some members were invited to join the scientific committee responsible for reviewing and rating abstracts that had been submitted for the conference.



Kevin Quaid speaking during Plenary 1



EWGPWD members Angela Pototschnigg (left) and Věra Ryšavá (right) at the 35th Alzheimer Europe Conference

Two members presented at the plenary session, four members gave presentations at the parallel sessions and two members had posters:

- Plenary Sessions:
 - Kevin Quaid – Going forward from Helsinki. What we need, not just what we want.
 - Gerda Van Tongerloo – In the silence of the symptoms, hear the echo of a soul.
- Parallel sessions:
 - Gerda Van Tongerloo – AI and co-creation for autonomy and wellbeing in dementia care.
 - Gerda Van Tongerloo – Exploring dementia through the lens of everyday life.
 - Jan Runar Eliassen – Empowering people with young onset dementia.
 - Věra Ryšava – As a person with dementia, this is the society I would love for me and my loved ones.
 - Gerda Van Tongerloo – Reframing case management around everyday life for people with dementia: a collaborative approach.
 - Lieselotte Klotz - ‘Be there until the end’: Connecting dementia identity, and sexuality through poetry.
- Posters:
 - Gerda Van Tongerloo – ‘We do this together’: Our reflective analysis on doing collaborative research involving people



European Working Group of People with Dementia and supporters, Senningerberg (Luxembourg), March 2025

with dementia and academic researchers and implications for future studies.

- Lieselotte Klotz – Empowering voices: The role of technology and participation in enhancing the lives of people with dementia.

In addition to the oral and poster presentations given at the conference, five members of the EWGPWD participated in an initiative focused on photography and storytelling organised by Ri-Scatti project and Federazione Alzheimer Italia. These members were asked to take pictures throughout the conference that portrayed their experiences, feelings and emotions during this event. A selection of the pictures was presented in a slideshow to the audience in the last session of the conference.

The EWGPWD also contributed to:

- Multiple articles to the AE Newsletter (12 articles from four different contributors)
- Multiple articles in Dementia in Europe Magazine (notably issues 47, 48 and 49)
- A significant volume of consultations via European-funded projects and research (for example AD-RIDDLE, EPND, Dorian Gray)
- JPND network projects
- Clinical trials related work
- European Medicine Agency (EMA) work
- Awareness raising work (events and conferences)
- Awards and campaigns
- Consultations in relation to ongoing work conducted by AE on the topic of barriers and facilitators to research participation and data sharing:
- one meeting (25 February) to discuss the findings of a literature review about research participation
- one meeting (17 March) to collect feedback for an online survey about research participation;
- four focus groups (26 August, 2 September, 10 September and 15 October) about experiences in research participation and data sharing in dementia research.
- A consultation in relation to the development of a survey on the topic of treatments for Alzheimer's disease
- A consultation on the topic of terminology surrounding Alzheimer's disease.
- A consultation on saliva biomarker collection procedures and associated guidance information.



Trevor Salomon speaking during Plenary 1

European Dementia Carers Working Group

The EDCWG is composed of people with current or prior experience of providing support and/or care to a person with dementia within the five years prior to their nomination. Members have different nationalities and backgrounds and are nominated by a national Alzheimer's association to join the group for a term of office of three years. The Chair of the EDCWG sits on the Board of Alzheimer Europe and has the same rights as other Board members.

Further information about the members can be found at: <https://www.alzheimer-europe.org/about-us/european-dementia-carers-working-group/members>

From January to June 2025, the EDCWG had the following members:

- Chair: Trevor Salomon (UK - England, Wales and Northern Ireland)
- Vice Chair: Sonata Mačiulskytė (Lithuania).
- Members:
 - Peter Banda (Slovakia)
 - Patrick Crosbie (Ireland)
 - Sylva Dneboská (Czechia)
 - Chris Ellermaa (Estonia)
 - Emil Emilsson (Iceland)
 - Annick Germeys (Belgium)
 - Zornitsa Karagyozyova (Bulgaria)
 - Barry Northedge (UK - Scotland)



European Dementia Carers Working Group, Brussels (Belgium), June 2025

- Hatice Sertaç Süslü (Türkiye)
- Liv Thorsen (Norway)
- Roslynn Vella (Malta)
- Olivera Vasilevska Danev (North Macedonia) and
- Christina Zioga (Greece).

From June to December 2025, the EDCWG had the following members:

- Chair: Trevor Salomon (UK - England, Wales and Northern Ireland)
- Vice Chair: Roslynn Vella (Malta)
- Members:
 - Bill Alexander (UK - Scotland)
 - Peter Banda (Slovakia)
 - Patrick Crosbie (Ireland)
 - Sylva Dneboská (Czechia)
 - Chris Ellermaa (Estonia)
 - Emil Emilsson (Iceland)
 - Annick Germeys (Belgium)
 - Zornitsa Karagyozeva (Bulgaria)
 - Hatice Sertaç Süslü (Türkiye)
 - Peter Thörngren (Sweden)
 - Liv Thorsen (Norway)
 - Olivera Vasilevska Danev (North Macedonia) and
 - Christina Zioga (Greece).

In 2025, Alzheimer Europe organised two in-person and three online meetings of the EDCWG which were attended as follows:

Date	Number of participants	Countries represented
26 February	13	8
3 and 4 June	14	14
2 July	15	14
5 and 6 October	15	14
27 November	10	10

In addition, other meetings that did not involve all members were held including:

- Regular meetings with the Executive of the EDCWG (Chair and Vice Chair).
- Regular meetings between July and October with members presenting at the Plenary session (AE conference) to prepare the speeches.

Similar to the objectives of the EWGPWD, much of the work undertaken by the EDCWG in 2025 focussed on exploring the ethical, social and practical implications of the use of technology by and for people with dementia and accompanying recommendations.

The EDCWG also contributed to the 2025 Yearbook which focused on the topic of transport and access to cultural life, recreation, leisure and sport. At the AE conference, three members of the EDCWG took part in a plenary session and one member in a parallel session:

- Plenary session:
 - Trevor Salomon – Chair of the session
 - Annick Germeys – Caring together. Technology as a partner in dementia care.
 - Roslynn Vella – The caregiver’s compass: Navigating policy to achieve patient-centred palliative care.
- Parallel sessions:
 - Patrick Crosbie – Perspectives from lived experience.

The EDCWG also contributed to:

- Multiple articles to the AE Newsletter (10 articles from four different contributors)
- Multiple articles in Dementia in Europe Magazine (issues 47, 48 and 49)
- A significant volume of consultations via European-funded projects and research (for example AD-RIDDLE, EPND, Dorian Gray).
- JPND network projects
- Clinical trials related work
- European Medicine Agency (EMA) work
- Awareness raising work (events and conferences)
- Awards and campaigns

Report on technology

In 2025, the EWGPWD and the EDCWG joined forces to explore the ethical, social and practical implications of the use of technology by and for people with dementia, and to develop recommendations. This work builds on an extensive report developed several years ago by a multidisciplinary working group, with expertise in technology, including researchers, ethicists, people with dementia, carers and health care professionals, led by Alzheimer Europe, targeted at developers and policy makers.



This discussion paper has been developed to promote reflection, raise awareness, and hopefully bring about change in relation to the development and use of technology. Members of the EWGPWD and the EDCWG singled out eight key issues that they found particularly meaningful and relevant. The two working groups met separately in person and online, each time building on each other’s work. Staff at Alzheimer Europe supported the working groups who identified the topics, debated the relevant issues, provided quotes, commented on drafts and agreed on the final text. The paper addresses a broad range of technologies. It covers the multitude of technological devices and systems that have become an integral part of our everyday lives, not just those that were developed for the specific needs and wishes of people with dementia.

The discussion paper is now available in pdf and printed form and has been shared with AE’s member associations and copies will be distributed at key events (e.g. at lunch debates and meetings of the European Disability Forum).

Objective 2: Making dementia a European priority

In 2025, Alzheimer Europe continued to monitor and contribute to EU policy developments to ensure dementia was prioritised and included in relevant policy discussions, coordinated the European Group of Governmental Experts on Dementia and the European Alzheimer's Alliance (EAA) and dedicated its 2025 Yearbook to an overview and comparison of national policies on transport and access to .

Contributing to EU policies

Alzheimer Europe monitored policy developments at the EU and national level, and included 48 news stories in the EU developments section of the newsletter and a further 15 in the Policy Watch section of the newsletter covering developments at the level of the World Health Organization and from Austria, France, Ireland, Italy, Sweden, the United Kingdom and Ukraine.

In the course of 2025, Alzheimer Europe also developed and collaborated with other European organisations to provide input on EU policies:

- On 31 January, Alzheimer Europe supported “A Joint Reaction to the Council Conclusions on Cardiovascular Health”, developed in partnership with the European Public Health Association (EUPHA) and other European health civil society organisations.
- On 7 February, Alzheimer Europe supported a joint statement from the EU4Health Civil Society Alliance expressing concerns about restrictions on civil society activities in the new mandate
- On 13 March, Alzheimer Europe supported a joint statement from the EU4Health Civil Society Alliance expressing concerns about delays to the 2025 Work Programme and the Operating Grants
- On 26 March, Alzheimer Europe signed a joint statement of the European Care Alliance, shared with Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness, Roxana Mînzatu, emphasising the need for prioritisation of policies relating to long-term care and implementation of the European Care Strategy
- On 7 April, Alzheimer Europe signed a statement coordinated by Civil Society Europe expressing concern about attacks on civil society organisations
- On 10 April, Alzheimer Europe signed an open letter to President Ursula von der Leyen, as part of the EU4Health Civil Society Alliance, calling for action to ensure support for European health civil society organisations
- On 2 May, Alzheimer Europe responded to four European Commission consultations on the next Multiannual Financial Framework (MFF):
 - Public consultation on the next MFF: EU funding for the single market, and cooperation between national authorities
 - Public consultation on the next MFF: Implementing EU funding with Member States and regions
 - Public Consultation - EU funding for competitiveness
 - Next MFF - EU funding for cross-border education, training and solidarity, youth, media, culture, and creative sectors, values, and civil society
- On 13 May, Alzheimer Europe signed a joint call, coordinated by InRAD (International Registry for Alzheimer's Disease and Other Dementias) Foundation, calling on the European Medicines Agency (EMA) to support collaborative real-world data infrastructure for Alzheimer's disease.
- On 12 June, Alzheimer Europe signed a joint call, coordinated by the European Patients' Forum (EPF) and Rare Diseases Europe



The European Parliament, Brussels (Belgium)


(EURORDIS), calling for a strong commitment to patient representation and voting in committees of the European Medicines Agency (EMA), as part of reforms to EU pharmaceutical legislation

- On 30 June, Alzheimer Europe supported the launch of the EU4Health Civil Society Alliance blueprint “Health4Europe”, proposing a future Health Programme for the EU
- On 3 July, Alzheimer Europe supported the development and launch of Civil Society Europe’s “Civil Society State of the Union 2025” report
- On 28 October, Alzheimer Europe signed a joint statement of the European Care Alliance, calling for long-term care to be prioritised in the next Multiannual Financial Framework (MFF)
- On 11 December, Alzheimer Europe supported a joint letter from the EU4Health Civil Society Alliance calling for the reinstatement of Operating Grants for civil society organisations in the EU4Health programme and expressing concern that the future Multiannual Financial Framework does not have a standalone budget for health.

Alzheimer Europe also closely followed the discussions on the introduction and authorisation of anti-amyloid treatments in Europe. After welcoming the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for a marketing authorisation of lecanemab in 2024, the association noted the delays with the approval process. In March 2025, Alzheimer Europe therefore sent an official letter to Olivèr Vårhelyi, the European Commissioner for Health and Animal Welfare, expressing grave concern about those delays and was ultimately able to welcome the formal approval of lecanemab by the European Commission in April 2025.

When it comes to the approval process of donanemab, Alzheimer Europe actively supported the re-examination process at CHMP level after the initial March 2025 rejection, submitted a third party intervention in favour of a positive evaluation and welcomed the reversal by the CHMP in July 2025 and the granting of the marketing authorisation by the European Commission in September 2025.

As next steps, Alzheimer Europe will monitor the discussions at national level when it comes to the health technology assessment, as well as the reimbursement and access policies for both treatments.



Update on the prevalence of dementia in Europe

Alzheimer Europe decided to update its 2019 report on the numbers of people affected by dementia in the European Union and published the “The Prevalence of Dementia in Europe 2025” report, which provides updated prevalence figures for the number of people living with dementia both for Europe as a whole, as well as the countries within.

The report builds upon Alzheimer Europe’s previous work in the “Dementia in Europe Yearbook 2019”. Alzheimer Europe adopted the same methodology, seeking out community-based studies published since the Dementia in Europe Yearbook 2019, from which new prevalence rates across 5-year age bands were derived. These updated prevalence rates were then applied to population projections for 2025 and 2050 taken from the UN World Population Prospects (UN WPP) data 2024.

For 2025, the number of people living with dementia is 9,065,706 for EU27 countries and 12,122,979 for EU and non-EU countries. The report also estimates that by 2050 there will be 14,335,788 people with dementia in EU27 countries and 19,905,856 people with dementia in EU and non-EU countries combined. This means that, by 2050, the estimated number of people living with dementia will increase by 58% in the EU27 countries, and by 64% in EU and non-EU countries combined.

To understand whether there had been any significant change in the estimated number of people with dementia, between 2019 and 2025, Alzheimer Europe used its estimates for EU27 countries, as a point of comparison. The overall numbers of people estimated to be living with dementia in the EU27 for the years 2025 and 2050, are broadly consistent across the two reports. However, among men, consistently higher prevalence rates were observed in each of the 70+ age bands, but in particular for the 70-74 band. The picture for women was generally more mixed.

The projected increase in overall numbers reinforces the call that Alzheimer Europe and its member associations have been making for many years: EU and national decision-makers must take action to ensure that society supports people with the condition, their families and carers to live well as well as possible.

European Group of Governmental Experts on Dementia

As in previous years, Alzheimer Europe provided the secretariat to the European Group of Governmental Experts on Dementia. In 2025, Alzheimer Europe organised two online meetings and one in person meeting of the European Group of Governmental Experts on Dementia:

- The online meeting of 10 June was attended by 24 representatives from national health and social ministries from 18 countries and observers from Alzheimer Europe, the European Commission (DG Research and Innovation and HADEA), the OECD and the World Health Organization.
- The hybrid meeting of 5 and 6 October in Bologna was attended by 24 representatives from national health and social ministries from 18 countries and observers from Alzheimer Europe, the European Commission (DG Research and Innovation and HADEA), the OECD and the World Health Organization.
- The online meeting of 11 November was attended by 17 representatives from national health and social ministries from 12 countries and observers from Alzheimer Europe, the European Commission (DG Research and Innovation and DG SANTE).



European Group of Governmental Experts on Dementia, Bologna (Italy), 5 October 2025

In total, ministry officials from 25 countries were represented during these meetings: Austria, Belgium, Bulgaria, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Luxembourg, Malta, Netherlands, Norway, Poland, Serbia, Slovenia, Sweden, Switzerland, Ukraine and United Kingdom.

European Alzheimer's Alliance

At the end of 2025, the total number of MEPs in the European Alzheimer's Alliance (EAA) stood at 89, representing 22 Member States of the European Union and seven out of eight political groups in the European Parliament. The group was chaired by the following MEPs who all acted as Co-Chairs: Nina Carberry (EPP, Ireland); Tilly Metz (Greens/EFA, Luxembourg); Romana Jerković (S&D, Croatia); Sirpa Pietikäinen (EPP, Finland); Vladimir Prebilič (Greens/EFA, Slovenia); Hilde Vautmans (Renew Europe, Belgium) and Dainius Žalimas (Renew Europe, Lithuania).

In addition to the co-chairs, Alzheimer Europe would also like to thank the following members of the EAA for their support in 2025:

- **Belgium:** Kathleen van Brempt (S&D); Johan Van Overtveldt (ECR); Hilde Vautmans (Renew Europe)
- **Bulgaria:** Radan Kanev (EPP); Andrey Kovatchev (EPP); Ilhan Kyuchyuk (Renew Europe); Tsvetelina Penkova (S&D); Kristian Vigenin (S&D)
- **Croatia:** Biljana Borzan (S&D); Romana Jerković (S&D); Tonino Picula (S&D); Tomislav Sokol (EPP)
- **Cyprus:** Costas Mavrides (S&D)
- **Czechia:** Ondrej Dostal (NI); Tomáš Zdechovský (EPP)
- **Denmark:** Kira Marie Peter-Hansen (Greens/EFA); Christel Schaldemose (S&D)
- **Estonia:** Urmas Paet (Renew Europe)
- **Finland:** Maria Guzenina (S&D, Finland); Merja Kyllönen (The Left); Sirpa Pietikäinen (EPP)
- **France:** François-Xavier Bellamy (EPP); Mélissa Camara (Greens/EFA); Laurent Castillo (EPP); David Cormand (Greens/EFA); Marie Dauchy (PFE); Christophe Gomart (EPP); Catherine Gristet (PFE); Céline Imart (EPP); Isabelle Le Callennec (EPP); Nadine Morano (EPP); Philippe Olivier (PFE); Mounir Satouri (Greens/EFA); Majdouline Sbai (Greens/EFA); Marie Toussaint (Greens/EFA)
- **Germany:** Alexandra Geese (Greens/EFA); Erik Marquardt (Greens/EFA); Angelika Niebler (EPP); Manuela Ripa (Greens/EFA); Terry Reintke (Greens/EFA)
- **Greece:** Tsiodras Dimitrios (EPP); Emmanouil (Manolis) Kefalogiannis (EPP); Nikos Papandreou (S&D); Elissavet Vozemberg-Vrionidi (EPP)
- **Hungary:** Tamás Deutsch (PFE); Enikő Győri (PFE); Kinga Gál (PFE); György Hölvényi (EPP); András Kulja (EPP)
- **Ireland:** Barry Andrews (Renew Europe); Lynn Boylan (The Left); Nina Carberry (EPP); Luke 'Ming' Flanagan (NI); Billy Kelleher (Renew Europe); Seán Kelly (EPP); Aodhán Ó Riordáin (S&D); Maria Walsh (EPP)
- **Italy:** Brando Benifei (S&D); Caterina Chinnici (EPP); Carlo Fidanza (ECR); Aldo Patriciello (PFE)
- **Lithuania:** Vytenis Povilas Andriukaitis (S&D); Petras Auštrevičius (Renew Europe); Vilija Blinkevičiūtė (S&D); Liudas Mažylis (EPP); Dainius Žalimas (Renew Europe)
- **Luxembourg:** Marc Angel (S&D); Charles Goerens (Renew Europe); Tilly Metz (Greens, EFA); Isabel Wiseler-Lima (EPP)
- **Poland:** Elżbieta Katarzyna Łukacijewska (EPP); Michał Szczerba (EPP); Anna Zalewska (ECR)
- **Portugal:** Marta Temido (S&D); Catarina Martins (The Left). Romania: Vlad Vasile-Voiculescu (Renew Europe)



Co-Chairs of the European Alzheimer's Alliance




Nina Carberry MEP (Ireland)



Tilly Metz MEP (Luxembourg)



Romana Jerković MEP (Croatia)



Sirpa Pietikäinen MEP (Finland)



Vladimir Prebilič MEP (Slovenia)



Hilde Vautmans MEP (Belgium)



Dainius Žalimas MEP (Lithuania)

- **Slovenia:** Matjaž Nemeč (S&D); Irena Joveva (Renew Europe); Vladimir Prebilič (Greens/EFA); Marjan Šarec (Renew); Romana Tomc (EPP); Milan Zver (EPP)
- **Spain:** Rosa Estaràs Ferragut (EPP); Juan Fernando López Aguilar (S&D); Idoia Mendia (S&D); Diana Riba i Giner (Greens-EFA); Ana Miranda Paz (Greens/EFA)
- **Sweden:** Pär Holmgren (Greens-EFA); Jonas Sjöstedt (S&D)

Members of the EAA were instrumental in supporting the organisation's campaign to make dementia a European priority and played an active role in Alzheimer Europe's activities by hosting three European Parliament workshops and lunch debates, by contributing to the Dementia in Europe magazine, and by informing Alzheimer Europe about relevant EU policy developments.


Yearbook on transport and access to cultural life, recreation, leisure and sport

In 2025, Alzheimer Europe focused on transport and access to cultural life, recreation, leisure and sport for its Yearbook. Alzheimer Europe developed a draft survey in January 2025 and tested it with a limited number of associations from Finland, France, Italy and Portugal. It was then rolled out to all members, with 31 national organisations responding to the survey.

Thanks to the responses of national associations, Alzheimer Europe was able to identify national policies and good practices from 31 countries, in relation to transport and access to cultural life, recreation, leisure and sport. In addition, 8 personal testimonials from members of the EWG-PWD and the EDCWG from seven countries were included.

On the basis of the national survey responses, Alzheimer Europe was able to develop a comparative report which included an overview of the current international and European policy context, a comparison of national dementia strategies and specific policies in relation to transport and access to cultural life, recreation, leisure and sport.

These results were published in the 2025 Yearbook which also included good practice examples, experiences of people with dementia and carers, as well as conclusions and recommendations for both European and national policymakers. Due to the length of the report, Alzheimer Europe opted not to print copies of the report but distributed the report in an electronic format via its newsletter mailing list (which includes over 10,000 subscribers).



Other policy developments and issues

Alzheimer Europe continued its collaboration with the EMA in 2025 as an accredited patient organisation and as a full member of EMA's Patients' and Consumers' Working Party (PCWP). Alzheimer Europe participated in the meetings of the PCWP either online or face-to-face (Amsterdam, the Netherlands).

At these meetings, EMA staff provided updates on:

- the reorganisation of the EMA working parties,
- medicines shortages,
- the new EU medical device regulation and in vitro diagnostics regulation,
- the new pharmaceutical legislation,
- real world data initiatives,
- electronic patient information forms,
- decentralised clinical trials and
- different EMA initiatives and projects, including the EMA work plan 2025-2028, EMA policy on competing interests, ACT-EU (Accelerating Clinical Trials in the EU), the European HTA Stakeholder Network and the EMA critical medicines list.

In June 2025, Alzheimer Europe joined more than 70 patient organisations in supporting a joint statement authored by Rare Diseases Europe (EURORDIS) and the European Patients' Forum (EPF), calling for the safeguarding of meaningful patient involvement in the European Medicines Agency (EMA), as part of reforms to the EU's pharmaceutical legislation.

In October 2025, Alzheimer Europe joined the ACT EU multi-stakeholder platform annual meeting aiming to review the key achievements of ACT EU since its inception and its impact on clinical research and discuss the current clinical trials landscape.

In December 2025, the EMA also organised a multistakeholder workshop on Patient Registries for Alzheimer's disease aiming to explore how to best use registries to collect data that can help fill evidence gaps on Alzheimer's disease, its prevention and its treatments. Alzheimer Europe actively participated in the workshop, presenting the results of the AE survey on research participation and data sharing, facilitating the participation of five national Alzheimer associations, and involving a member of the EWGPWD as an opening speaker.

Finally, Alzheimer Europe continued to engage with the WHO at both a global and European level. Alzheimer Europe participated in meetings of the pan-European Mental Health Coalition of WHO Europe. Furthermore, Alzheimer Europe contributed to the update of the WHO Dementia Risk Reduction Guidelines, as part of the evidence review team for social contact. The organisation also contributed to a manuscript on the distribution of modifiable risk factors in low and middle income countries, in collaboration with the WHO and researchers from the Netherlands, UK, Australia, Mexico, Nigeria, China, India and Russia to be submitted in March 2026.

Objective 3: Changing perceptions and combating stigma

In 2025, Alzheimer Europe launched the fourth edition of its anti-stigma award in collaboration with the Alzheimer Europe Foundation and sponsors C2N Diagnostics, Lilly and Roche

Alzheimer Europe anti-stigma award

Alzheimer Europe, in collaboration with the Alzheimer Europe Foundation and C2N Diagnostics, Lilly and Roche, launched the call for the 2025 anti-stigma award for a European artist active in the field of painting or



Nina Carberry MEP (Ireland), host of the Anti-Stigma Award 2025 (in the green blazer) with the winners, runners-up and honourable mentions

photography for their work which contributed to combating stigma and promoting a positive image of dementia and people living with dementia.

The award was open to artists established in a member country of Alzheimer Europe for work which was produced in the past three years (2022-2025).

45 applications from 17 countries were received and reviewed by the Jury which was comprised of:

- Alzheimer Europe Foundation: Heike von Lützu-Hohlbein, Trevor Salomon and Iva Holmerová
- Alzheimer Europe: Maria do Rosário Zincke dos Reis and Mario Possenti
- European Working Group of People with Dementia: Lilo Klotz and Kevin Quaid
- European Dementia Carers Working Group: Emil Emilsson and Zornitsa Karagyzova
- Roche: Jannice Roeser
- Lilly: Laura Campo
- C2N Diagnostics: Daniel Connell

The nine short-listed artists were invited to attend the award ceremony which took place in Brussels on 2 December. The award ceremony was hosted by Nina Carberry, MEP (Ireland) and the awards were presented by members of the Jury:

- First place with a cash prize of EUR 5,000 was presented to Alex Kornhuber, Ireland for “Keepsake Chronicles”
- Second place with a cash prize of EUR 2,500 was presented to Desideria Care e.V., Germany for its Openair photo exhibition “Demenz neu sehen”
- Third place with a cash prize of EUR 1,250 was presented to Bálint Szajki, Hungary for “In Sickness and in Health”
- Honourable mentions were presented to:
 - João Barbosa, Portugal for “Walking the Talk for Dementia: A Journey Beyond the Diagnosis”(2024)
 - Peter Gaymann and Thomas Klie, Germany for DEMENSCH
 - Mathilde Parquet, France for “Aimants, Aidants”
 - Simon Móricz Sabján, Hungary for “What the Light Remembers”
 - Max W. Schulte, Ireland for “Walk the Talk for Dementia - Stepping Forward for Understanding”
 - Wouter van Wessel, Luxembourg for “A Calm Gaze”

Other activities to combat stigma

To promote the work carried out by Alzheimer Europe to combat stigma, Dianne Gove, the organisation’s Director for Public Involvement and Ethics participated in an online question and answer session with touch-NEUROLOGY discussing how stigma affects people living with dementia and strategies to raise awareness of this topic.

Objective 4: Raising awareness of brain health and prevention

In 2025, Alzheimer Europe continued to include trials on dementia prevention in its Clinical Trials Watch, collaborated in a number of EU projects on brain health and prevention and supported research communication activities on these topics.

Prevention trials

In 2025, Alzheimer Europe paid particular attention to monitor databases on clinical trials to identify trials investigating drugs or other interventions for the prevention of Alzheimer’s dementia or other forms of dementia. The organisation was able to identify five phase II trials, four phase III trials and one non-drug trial which were included on the Clinical Trials Watch section of the organisation’s website.

EU research projects on brain health

The portfolio of EU projects, in which Alzheimer Europe is involved, continues to grow, and the following projects are focused on improving the identification of people at risk of developing dementia, as well as the development of prevention or brain health strategies:

- ADIS
- AI-MIND
- DORIAN GRAY
- eBRAIN-Health

- FluiDx-AD
- LETHE
- Multi-MeMo
- Pattern-Cog
- PREDICTFTD
- PREDICTOM
- VirtualBrainCloud

More detailed information on these projects can be found in the project section below. Alzheimer Europe is including people at risk of developing dementia in its Public Involvement and communication activities on these projects.

Contributing to publications and initiatives on brain health

In 2025, Alzheimer Europe collaborated with several research projects on brain health and dementia risk reduction, co-authoring four scientific articles on topics including adherence to lifestyle interventions and new digital tools for personalised interventions to reduce dementia risk. Alzheimer Europe also continued its collaboration with the European Task Force on Brain Health, co-authoring a publication that identified opportunities and challenges for the implementation of Brain Health Services from a range of different perspectives, including the patient and societal perspectives.

In March 2025, Angela Bradshaw, Director for Research, contributed to a panel discussion on dementia prevention and risk reduction broadcast by the Luxembourg radio station RTL and in July, she contributed an article entitled “European perspectives on dementia prevention: Can lifestyle changes reduce risk?” to Open Access Government.

A special supplement of the organisation’s “Dementia in Europe” magazine was dedicated to brain health with articles on:


- The findings of the Lancet Commission on Dementia Prevention, Intervention and Care
- Information on Eu funded projects AD-RIDDLE, MultiMeMo and LETHE
- Overview of the FINGER study and an interview with its Principal Investigator Miia Kivipelto
- Brain health initiatives by Alzheimer’s associations in Armenia, Netherlands, Switzerland and the UK (Scotland)
- Perspectives on risk reduction by people with dementia and carers.



Prevention trials identified and included in Alzheimer Europe’s Clinical Trials Watch database in 2025

Phase II trials				
Company	Study	Drug candidate	Population	Target
AC Immune	ABATE	ACI-24.060	Prodromal Alzheimer's disease	Amyloid-related (Immunotherapy)
Merck	MK-2214-004	MK-2214	Early Alzheimer's disease	Immunotherapy (Tau)
Novartis	VHB937	VHB937	Early Alzheimer's disease	Amyloid-related (immunotherapy)
Imperial College London	MET-FINGER	/	At risk of developing Alzheimer's dementia	Multidomain intervention
Janssen	Retain	JNJ-64042056	Preclinical Alzheimer's disease	Immunotherapy (Tau)
Phase III trials				
Company	Study	Drug candidate	Population	Target
Roche	TRAVELLER		N/A – pre-screening study to identify people who are best suited to participate in one of Roche's Alzheimer's disease clinical studies	
Roche	FRONTIER 1	Trontinemab	Early symptomatic Alzheimer's disease	Amyloid-related (Immunotherapy)
Roche	FRONTIER 2	Trontinemab	Early symptomatic Alzheimer's disease	Amyloid-related (Immunotherapy)
Eli Lilly	TRAILRUNNER-ALZ 3	Remternetug	Early Alzheimer's disease	Amyloid related (immunotherapy)
Non-drug trials				
Company	Study	Remternetug	Target	
Maastricht University	LIGHT		Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) at risk of dementia	Lifestyle Intervention

Our members are helping people with dementia and their carers in 36 countries



Objective 5: Strengthening the European dementia movement

In 2025, Alzheimer Europe continued to organise its Alzheimer's Association Academy, the capacity building workshops for representatives of national Alzheimer's associations, involved its Board in the monitoring of its activities and finances, organised a successful Annual General Meeting in Brussels (in June), as well as an online Annual General Meeting (in November), and continued its collaboration with other European and international organisations.

Alzheimer's Association Academy

In 2025, Alzheimer Europe organised two in-person and seven online Alzheimer's Association Academy meetings which were attended as follows:

A total of 34 European countries were represented at these capacity building workshops. Recordings of the meetings were made available to all representatives of national member organisations.

Alzheimer Europe Board and Annual General Meetings

The Board of Alzheimer Europe met five times in 2025 for two online and three in-person meetings in Luxembourg and Brussels. The Board was able to fulfil its role of supervising and monitoring the association's progress against its Work Plan and Budget. At each meeting, the Board received a report of the organisation's finances and activities. The Board was also able to approve documents for adoption by the association's members, such as the 2024 Annual Report, the new Strategic Plan (2026-2030) and the 2026 Work Plan and Budget.

Alzheimer Europe organised two Annual Meetings. At the in-person meeting in Brussels in June, 29 out of 36 full members were present

or represented by proxy. At this meeting, all five provisional members (Armenia, Lithuania, North Macedonia, Serbia and Ukraine) were accepted as full members of Alzheimer Europe and the AGM approved the 2024 Annual Report and Financial Report.

At the online AGM on 24 November 2025, 35 out of 41 full members were present or represented by proxy and the meeting adopted the 2026 Work Plan and Budget and new Strategic Plan of Alzheimer Europe (2026-2030).

Collaboration with other organisations

Alzheimer Europe continued its close collaboration with the INTERDEM network of European researchers involved in psychosocial research in dementia. In 2025, Alzheimer Europe:

- hosted the Annual General Meeting of INTERDEM on 5 and 6 October prior to the Annual Conference in Bologna and dedicated four parallel sessions to activities and research carried out by the group,
- collaborated with the INTERDEM Academy to launch 10 bursaries for early stage researchers from underrepresented countries and organised a special session for "Dementia Researchers of the Future" which was chaired by INTERDEM Academy Chair Fania Dassen and the Alzheimer Europe Foundation Treasurer Iva Holmerová,
- contributed to the INTERDEM interest group on prevention and risk reduction and joined the International Advisory Board of the INTERDEM Academy.

Alzheimer Europe also collaborated with the European Alzheimer's Disease Consortium, a network of research centre of excellence in Europe. Representatives of Alzheimer Europe participated in and contributed to the Consortium meetings in Belgrade in March and Edinburgh in



Public Affairs meeting, Brussels (Belgium), 3 June 2025

In 2025, Alzheimer Europe updated the memorandum of understanding governing the collaboration with the European Academy of Neurology (EAN). The organisation's Executive Director attended meetings of the EAN Panel for Dementia and Cognitive Disorders' Management Board, and Alzheimer Europe participated in the EAN coordinated Brain Health Mission.

As a full member of the European Disability Forum and the European Patients' Forum, Alzheimer Europe continued its close collaboration with both organisations. In 2025, Alzheimer Europe was also accepted as a member of the European Public Health Alliance.

Finally, Alzheimer Europe partnered with other organisations in the European Care Alliance, coordinated by COFACE – Families Europe to contribute to EU discussions and policy initiatives in the field of informal and professional care.

October 2025.

Date	Topic	Number of participants	Countries represented
28 January	Involvement in HTA, pricing and reimbursement	36	9
22 February	Technology in dementia care: challenges and opportunities	36	14
3 June	Public Affairs meeting in Brussels on Preparing for new disease-modifying therapies in Europe, Prevalence of dementia risk factors across countries in Europe: initial findings from the SHARE survey and Priorities for brain health and risk reduction	37	21
24 June	Mild Cognitive Impairment: terminology, support and services	45	11
15 July	Awareness campaigns	26	15
16 September	Working with parliamentarians and Interest Groups	30	12
18 November	Involving under-represented groups in dementia research	22	17
2-3 December	Public Affairs meeting in Brussels on National dementia strategies, Updating the report on the prevalence of dementia in Europe, New treatments for Alzheimer's disease and Clinical trials to prevent progression to symptomatic stages of Alzheimer's disease	41	24
9 December	Alzheimer Europe yearbook on transport and access to cultural life, recreation, leisure and sport	26	13

Objective 6: Supporting dementia research

In 2025, Alzheimer Europe continued its collaboration with a growing number of EU projects (see chapter 1.5.1. below), contributed to Public Involvement (PI) activities of these projects, communicated about research findings via its newsletter, website and social media and organised its 35th Annual Conference in Bologna from 6 to 8 October 2025.

Public Involvement in dementia research

Alzheimer Europe is actively involved in a range of EU projects. In these projects, Alzheimer Europe ensures that the views of people with dementia and their carers are included through the organisation’s PI activities as well as contributing to the ethical issues raised by research projects and supporting the communication activities of these projects.

The European Working Group of People with Dementia (EWGPWD) and the European Dementia Carers Working Group (EDCWG) actively supported the PI activities of Alzheimer Europe in EU-funded research projects, and provided important feedback through consultations for the following projects: AD-RIDDLE, AI4HOPE, Dorian Gray, eBRAIN-Health, EPND, FluiDx-AD, HOMEDEM. Lethe, Multi-MeMo, Pattern-Cog, PROMINENT and PREDICTOM.

A full list of EU projects and PI activities can be found in the project section on pages 29-38.

Research communication

For the dissemination of research findings via its newsletter, website and conference, Alzheimer Europe ensured that it not only focused on basic and clinical science, but also involved researchers and academics with a psychosocial, care, mental health, socio-economic or health systems background. Alzheimer Europe issued 11 monthly e-newsletters (July and August combined), featuring updates on the organisation’s activities and those of its member associations. Each edition included progress reports on European projects involving Alzheimer Europe, relevant national and EU policy developments, scientific advances, human-interest stories, new resources and publications, and job opportunities in the dementia field. The newsletters also regularly published first-person accounts by people living with dementia—many contributed by members of the EWGPWD and national dementia working groups.

A total of 485 news stories (519 in 2024) were included in these newsletters which can be further divided as follows:

- 158 about Alzheimer Europe and its EU projects (159 in 2024)
- 104 scientific developments (104 in 2024)
- 89 members’ news (97 in 2024)
- 52 EU developments and activities of European Alzheimer’s Alliance (65 in 2024)
- 38 on living with dementia and dementia in society (45 in 2024)
- 28 new publications, resources, job opportunities and training (27 in 2024)
- 16 national policy developments (22 in 2024)

These newsletters were delivered to the following number of recipients and opened as follows:

Month	Delivered to	Opened by	Percentage
January	10,241	4,283	42%
February	10,233	4,033	39%
March	10,175	3,794	37%
April	10,145	4,208	41%
May	10,117	4,127	41%
June	10,052	3,756	37%
July-August	9,427	3,871	41%
September	10,095	4,174	41%
October	10,841	4,269	39%
November	10,840	4,416	41%
December	9,860	4,246	43%

When it comes to the AE website, the number of visitors and users remained largely unchanged with some variations in months:

Month	Users (2023)	Users (2022)
January	5,600	4,300
February	4,900	4,700
March	5,500	5,800
April	6,800	5,500
May	5,600	6,700
June	6,200	5,600
July	4,700	5,300
August	4,600	4,600
September	5,800	5,700
October	6,500	6,600
November	4,700	5,100
December	4,500	4,500
Total:	65,400	64,400
Average:	5,450	5,367

The association’s social media accounts attracted more followers, with over 10,600 on Facebook, over 1,500 on Instagram, and over 8,000 on LinkedIn. The organisation also had 486 YouTube subscribers by the close of 2025.

X and LinkedIn were the two social media platforms most frequently used by Alzheimer Europe and its staff during 2025. However, due to changes in usability following X’s rebranding, the statistics on tweets

and impressions were no longer available, and there was a notable shift towards a more negative atmosphere on the platform, leading to many of Alzheimer Europe’s contacts departing to other platforms such as Bluesky.

Alzheimer Europe decided, as at the end of the year, to close its X account and opened a new account on Bluesky in September. LinkedIn has been used more frequently and with better results than in previous years, with a noticeable increase in interactions and responses from followers, so this platform will be a focus of the organisation’s communications in the coming year.

Alzheimer Europe Conference

The 35th Alzheimer Europe Conference (#35AEC) “Connecting science and communities: The future of dementia care”, took place at the Bologna Fiera in Bologna, Italy from 6 to 8 October 2025. The conference was held as on-site event. In total, 1518 participants registered from 43 countries.

	2025 Bologna	2024 Geneva
Academics/Researchers	529	264
AE staff & volunteers	283	175
Health or social care professionals	354	145
Industry representatives	114	98
Students	115	83
Carers	45	49
People with dementia	42	34
Policy makers	20	12
Civil servants	14	8
Press	2	5
Total	1518	973

As in previous years, the conference was formally opened by the Chairpersons of Alzheimer Europe, the host associations chairpersons from Alzheimer Uniti Italia and Federazione Alzheimer Italia. The ministry of health Orazio Schillaci sent a written welcome message to the attendees.

On the agenda were over 900 presenters (286 oral presentations, 68 quick oral presentations and 546 poster presentations), who shared their research, knowledge and experience in an atmosphere of collaboration and solidarity.

The plenary sessions were dedicated to “Dementia as a European and national policy and research priority – as seen by people with dementia and their carers” (organised and moderated by the European Working Group of People with Dementia), gender and dementia, the introduction of new AD treatments and other types of dementia (fronto-temporal dementia, childhood dementia, prion disease and Lewy Body dementia).

In addition to these plenaries, delegates at #35AEC had a choice of 60 different parallel sessions and 10 special symposia organised by the sponsors of the Alzheimer Europe Conference.

As in previous years, the Alzheimer Europe Foundation provided bursaries for people with dementia to attend the conference and supported the costs of the meetings of the European Working Group of People with Dementia and the European Dementia Carers Working Group, which took place prior to the Conference. In 2025, the Alzheimer Europe Foundation also provided bursaries for early-stage researchers from underrepresented countries to attend the conference and partnered with the INTERDEM Academy to host the session dedicated to the “dementia researchers of the future”. In addition, Frontiers in Dementia provided an award for the best presentation of an early stage researcher at that session.

In the evaluation of the Annual Conference, 93% of participants said that they would be happy to recommend the Alzheimer Europe Conference to a colleague.



35th Alzheimer Europe Conference
Connecting science and communities:
The future of dementia care
Bologna (Italy), 6 - 8 October 2025 #35AEC

Snapshots from the 35th Alzheimer Europe Conference




The conference was attended by over 1,500 delegates



Speakers at the Opening Ceremony (Ltr: Giovanni Gordini, Clelia d'Anastasio, Maria do Rosário Zincke dos Reis, Roberta Toschi, Mario Possenti)



Lilly special symposium at 35AEC, with participation of Italian Senator Beatrice Lorenzin, Bologna (Italy), 7 October 2025



Plenary 3 focused on preparing for new AD treatments and was moderated by Angela Bradshaw, Director for Research



The INTERDEM network hosted its Annual Meeting in Bologna



Biogen sponsored a special symposium at 35AEC, called "Prioritising Alzheimer's Disease in Europe: Next steps for Policy Action"



Plenary 4 looked at some of the less common types of dementia and was moderated by Jean Georges, Executive Director



"Dementia Researchers of the Future" session

Other activities and projects

Involvement in EU projects

Alzheimer Europe was a full partner in a number of projects funded by the European research programmes Horizon 2020, Horizon Europe, the Innovative Health Initiative (IHI) and the Innovative Medicines Initiative (IMI). The organisation also participated in two JPND (Joint Programme Neurodegenerative Diseases Research) projects and one ERA PerMed project funded by the Fonds National pour la Recherche (FNR) in Luxembourg.

In these projects, the organisation ensured that the views of people with dementia, carers and Alzheimer's associations were included, contributed to the discussion of the ethical issues and policy challenges raised by the projects and supported or led the communication, dissemination and stakeholder engagement activities.

In 2025, Alzheimer Europe was a full partner in the following projects:

ADIS



ADIS project closing meeting, Bonn (Germany), 25-26 June 2025

ADIS stood for "Early Diagnosis of Alzheimer's Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances" and was a project funded through the JPND and Luxembourg FNR. The three-year project started on 1 July 2022.

ADIS focused on the question of how an earlier diagnosis of Alzheimer's disease (AD) can be achieved in the future.

Two concrete objectives were to evaluate whether blood-based biomarkers derived from special types of immune cells and sleep disturbances would allow to reliably distinguish AD patients at different stages of the disease from healthy subjects; and to understand the extent to which sleep disturbances might influence blood-based biomarkers.



The actions included a clinical study with 75 participants (25 with AD, 25 with mild cognitive impairment and 25 cognitively normal participants) who were assessed via standard questionnaires, a smart watch (worn at home), an augmented reality game (to monitor cognition) and blood sampling.

From each of the blood samples, researchers measured different molecular markers, including measurement at the cellular level. They then used statistical as well as advanced computational approaches (including Artificial Intelligence) to find patterns in the data generated by the study. This aimed to help researchers evaluate whether measuring blood-based biomarkers and sleep disturbances would be instrumental in detecting AD at an early disease stage.

Alzheimer Europe was represented by Chris Bintener and Soraya Moradi-Bachiller.

In 2025, they:

- represented Alzheimer Europe in the monthly telephone conference calls
- maintained the website & social media channels
- developed other communication materials such as an extended project clip and interviews with early-career researchers
- helped plan the final ADIS symposium which took place in Bonn, Germany on 25-26 June 2025
- organised and participated in a Public Involvement event in Barcelona, Spain on 6-7 February 2025
- contributed to the efficient communication of the project via the Alzheimer Europe website, social media channels, Dementia in Europe Magazine, newsletter and events.

AD-RIDDLE

The AD-RIDDLE (Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement) project, which has been funded through the Innovative Health Initiative for a period of 5 years (2024-2029) aims to transform how AD is detected and diagnosed, prevented and treated across healthcare settings. AD-RIDDLE aims to facilitate the implementation of new disease-modifying therapies and harness the huge potential benefits of preventive multidomain interventions, which provide new opportunities for early detection, prevention and treatment of Alzheimer's disease (AD) and dementia. AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable healthcare systems and





AD-RIDDLE project General Assembly, London (United Kingdom), 10 June 2025

practitioners to improve the management of AD and dementia across diverse patient populations.

The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and blood-based biomarkers, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach. The toolbox usability and efficacy will be tested in real-world settings. The modular and flexible design of the AD-RIDDLE platform will facilitate broad uptake from different healthcare systems, also aiming to advance research to develop cost-effective preventive therapies for AD and other dementias.

Alzheimer Europe was represented by Cindy Birck, Angela Bradshaw, Ana Diaz, Sarah Campill, Lukas Duffner and Dianne Gove.

In 2025, they:

- attended a General Assembly Meeting on 10-11 June (London, United Kingdom)
- represented Alzheimer Europe in online Steering Committee meetings
- collaborated with project partners to set up a global and country-specific Advisory Boards in Sweden, Finland, the Netherlands, Italy, Spain and the UK, involving older adults and people with or at risk of dementia from these countries
- coordinated online meetings of the Advisory Boards in collaboration with project partners and produced reports with summaries of feedback for each of the meetings
- finalised a policy analysis on dementia prevention, brain health strategies and screening platforms
- finalised a literature review on ethical challenges linked to early detection and screening of dementia

- collaborated with project partners to launch a suite of AD-RIDDLE communication channels and tools
- maintained the AD-RIDDLE website and social media channels, creating infographics, news items and a press release to highlight new developments for the project
- contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events
- featured AD-RIDDLE in an article in the Dementia in Europe Magazine, and during a conference symposium at the Annual Conference in Bologna
- featured AD-RIDDLE in the Brain Health Supplement (October 2025)
- collaborated with project partners to present AD-RIDDLE at a Public Affairs meeting of Alzheimer Europe.


AI-MIND

The goal of AI-MIND (Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment) is to develop novel, AI-based tools to support healthcare professionals in timely diagnosis and interventions for patients. The researchers hope that complex, labour-intensive, costly and poorly predictive screening methods for mild cognitive impairment (MCI) will eventually be replaced by automated diagnostic screening tools driven by artificial intelligence (AI), permitting the timely and accurate prediction of which people with MCI will eventually develop dementia.

Alzheimer Europe was represented in this project by Cindy Birck and Dianne Gove.

In 2025, they:

- attended the General Assembly Meetings on 5-7 May (Bodo) and 15-16 December (Rome)
- represented Alzheimer Europe in the AI-Mind Executive Board Committee and its quarterly telephone conferences



- contributed to the production and maintenance of the communication tools
- contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events
- contributed to the development of a policy brief that was launched at the Lunch Debate hosted at the European Parliament in Brussels, organised by Alzheimer Europe on 2 December
- organised an AI-Mind session at the annual conference in Bologna
- published a special supplement to the 48th edition of Dementia in Europe magazine dedicated to the AI-Mind project.

- launched this leaflet with a member of the European Working Group of People with Dementia at a pre-conference meeting in May 2025, organised by the European Association for Palliative Care in Helsinki.
- attended monthly meetings for various work packages
- provided input on relevant tasks/activities.

AI4HOPE



AI4HOPE project consortium meeting, Bonn (Germany), 15 January 2025

Initiated in 2024, the Artificial intelligence-based health, optimism, purpose and endurance in palliative care for dementia (AI4HOPE) project aims to develop digital solutions supporting palliative care for people with mild to moderate dementia. This is done using novel technology (e.g. virtual reality) and artificial intelligence. Individual components of AI4HOPE, for instance, include methods for detecting distress, as well as delivering targeted interventions using elements of gamification, mindfulness and sensory stimulation. The main outcome of AI4HOPE is the feasibility and usefulness of developed technical solutions.

Within AI4HOPE, AE is leading the Public Involvement activities, providing feedback on processes and products developed. Moreover, AE assists in AI4HOPE's communication activities led by project management company Terra Globus. Within the project, AE was represented by Dianne Gove and Lukas Duffner.

In 2025, they:

- contributed to the internal AI4HOPE newsletter
- continued to address the concept of palliative care in dementia with the EWGPWG and the EDCWG
- developed a leaflet on palliative care in dementia targeted at healthcare professionals



DORIAN GRAY



DORIAN GRAY stands for “Devising a personalised risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes” and is a project funded by the European Union and led by the University of Brescia (Italy) with a budget of 11 million euros distributed across 24 partners and with the official start date of 1 January 2025. DORIAN GRAY aims to uncover the links between cardiovascular disease and mild cognitive impairment and develop an integrated approach to promote resilience and improve overall health in the ageing population. It will start with the analysis of data available from people with cardiovascular disease in which mechanisms leading to MCI are enhanced, and thereafter the factors aggravating the onset and progression of cognitive impairment in the general population with cardiovascular risk factors will be defined.

Alzheimer Europe was represented by Soraya Moradi-Bachiller and Cindy Birck.

In 2025, they:

- took part in two General Assembly meetings; one on 28 February in Brescia, and the other online on 29 April



- set up the Public Involvement Board for this project
- organised and facilitated several online meetings with the DORIAN GRAY Public Involvement Board on 26 May, 10 June, 18 June, 27 August, 1 September and 2 December.
- prepared drafts of final deliverables on the social and ethical implications of eBRAIN-Health technologies and Public Involvement activities that are due in 2026.

eBRAIN-Health



eBRAIN-Health researchers at EWGPWD consultation, Senningerberg (Luxembourg), 25 March 2025

eBRAIN-Health is a four-year Horizon Europe funded research project which was launched in July 2022 and involves 20 partners. In eBRAIN-Health, a large variety of data sources will be brought together in a GDPR-compliant research platform to support the development of digital representations of the brain. These “digital twins” will allow researchers to conduct innovative brain research within a powerful digital platform that keeps patient data secure and confidential. In addition, digital twins have the potential to improve our understanding of brain function and disease at an individual level, improve diagnosis and risk prediction and optimise potential therapies.

Alzheimer Europe’s role in the project is to lead the Public Involvement (PI) and ethics activities (led Ana Diaz with support from Dianne Gove and Faye Forsyth) and to contribute to communications and outreach work (led by Ange Bradshaw).

In 2025, they:

- attended virtual project meetings, including a general assembly and technical coordination meetings
- disseminated eBRAIN-Health activities via the Alzheimer Europe newsletter and social media channels
- conducted public involvement activities including a face-to-face meeting with members of the Advisory Board in Luxembourg
- participated in a meeting with the project Legal and Ethics Advisors
- prepared a deliverable report on the eBRAIN-Health symposium at the 2024 Alzheimer Europe conference, as well as policy-facing activities



EPND



EPND project General Assembly meeting, Brussels (Belgium), 6 November 2025

The goal of the Innovative Medicines Initiative (IMI) funded “European Platform for Neurodegenerative Diseases” project is to accelerate the discovery of diagnostics and treatments for neurodegenerative diseases by removing barriers to data and sample sharing and fostering collaboration. The consortium is led by the University of Maastricht, University of Leicester, UCB Biopharma and Gates Ventures, and includes a further 25 partners from academic institutions, pharmaceutical companies, SMEs and patient organisations. EPND is funded for a period of five years from November 2021. The project will create a platform that will enable the sharing of high-quality bio-samples and clinical data from research cohorts on ageing and neurodegeneration, performing a series of clinical case studies that will advance research on multimodal biomarkers as well as testing and validating the EPND platform. EPND will also develop recommendations to address ethical, legal, regulatory and technical challenges in data and sample sharing and biomarker validation.

Alzheimer Europe co-led the stakeholder involvement and communication activities of the project, leading a task on PI and participated in work packages on the establishment of the technical platform, ethical and legal issues, cohort interactions and sustainability. Alzheimer Europe was represented by Angela Bradshaw and Dianne Gove.

In 2025, they:

- participated in the in-person Annual Meeting (Brussels, Belgium), as well as monthly Management Board and work package meetings
- organised consultations online and in person with the members of the EWGPWD and the EDCWG to finalise the lay glossary



- organised online and face-to-face consultations with members of the EWGPWD and the EDCWG to discuss the concept of citizen science and data sharing
- published 2 deliverables detailing activities of the Stakeholder Engagement Framework, and providing an interim report on communication and dissemination activities
- coordinated the project's social media channels (Twitter/X, LinkedIn) and updates to the project's website, creating new content, publishing newsletters, brochures and information sheets on the project; also hosting two public webinars on the EPND Hub, and on the biomarker case studies carried out by the project
- supported EPND's presence at the AD/PD conference and other scientific meetings, developing posters and other materials to raise awareness of the project
- contributed to the efficient communication of the project via the AE website, social media, newsletter and events, including the 2025 Alzheimer Europe conference in Bologna.

FluiDx-AD



FluiDx-AD project consortium meeting, Bologna (Italy), 9 October 2025

The FluiDx-AD project, funded by the European Union's Horizon Europe programme with a budget of EUR 7,699,219.38 for three and a half years, aims to improve the early diagnosis and management of Alzheimer's disease (AD). The project brings together a consortium of ten partners across Europe, FluiDx-AD aims to make the diagnostic process faster and more accessible, by developing three clinical tests that use minimally invasive techniques:

- SalivaDx-AD: An easy-to-use, at-home saliva test for population-wide detection of individuals at risk of developing AD in its prodromal stages.
- PlasmaDx-AD: A minimally invasive and cost-effective blood test for high-precision confirmatory diagnosis for individuals with suspected AD.
- BloodCellDx-AD: A minimally invasive, whole blood ex vivo test system to evaluate the risk of amyloid-related imaging

abnormalities (ARIA), to support patient eligibility assessments and ARIA monitoring for anti-amyloid therapies

Alzheimer Europe is leading the work on Public Involvement and Ethics as well as on communication and dissemination. Alzheimer Europe was represented in this project by Faye Forsyth, Dianne Gove and Christophe Bintener.

In 2025, they:

- finalised work on the communication strategy, including brand guidelines, logo, press release, public facing website and social media channels as well as a short introduction video
- facilitated an interview with the Scientific Coordinator in the February 2025 edition of the Dementia in Europe Magazine and disseminated FluiDx-AD activities via the Alzheimer Europe newsletter and social media channels as well as those of the project
- attended the AGM in Bologna, Italy in October
- Facilitated in-person meetings between members of the EWGPWG, EDCWG and the FluiDx-AD saliva device creators, provided detailed feedback on improvements that can be made to the test (SalivaDx-AD device) and the accompanying instructions
- completed a rapid systematic review of ethical and social issues related to fluid biomarkers use in relation to treatment decisions
- produced summaries and reports of the latter, including a draft publication for a peer review journal (rapid review) as well as a prototype online visualisation script of the findings
- participated in regular work package and clinical meetings
- completed required project deliverables within the designated timeframe.

LETHE



The LETHE project showcasing some results at the EGI Conference, Santander (Spain), June 2025

LETHE (A personalised prediction and intervention model for early detection and reduction of risk factors causing dementia, based on Artificial Intelligence and distributed Machine Learning) was a four and a half-year, Horizon 2020-funded project which aimed to prevent cognitive

decline in older adults using a multi-domain lifestyle intervention built on a person-centred digital solution.

Alzheimer Europe contributed to the Public Involvement as well as communication and dissemination activities. Alzheimer Europe was represented by Christophe Bintener and Ana Diaz.

In 2025, they:

- collaborated with project partners to identify topics for the Advisory Board and to develop accessible documents for the meetings
- coordinated the regular online meetings of the Lethe Advisory Board which is composed of seven people with and without dementia from Austria, Italy, Finland and Sweden
- produced reports with summaries of feedback for each of the meetings with the members of the Advisory Board
- participated in the bi-weekly scrum meetings and collaborated with i2G and The Lisbon Council for alignment in communication and dissemination activities
- supported project outreach and awareness-raising activities through AE social media, newsletter, Dementia in Europe Magazine and website
- participated as co-author in two peer-reviewed articles about the project
- supported the planning, organisation of, moderation, and dissemination of the LETHE webinar series
- provided feedback on the LETHE website and social media posts for further development and reviewed the final communication deliverable.

Multi-MeMo

Multi-MeMo stands for “Shorter- and longer-term mechanisms of multimodal interventions to prevent dementia”. Funded by JPND, the project aligns experimental molecular, cellular, and animal models with a very strong array of unique multi-national multimodal human trials which have already demonstrated multi-year cognitive and functional benefits across the entire continuum from at-risk to prodromal disease stages. This will allow comprehensive in-depth analysis of multiple relevant molecular and cellular mechanisms that cannot be clarified from human trials alone, as well as to rapidly validate the identified mechanisms for clinical relevance using successful long-term (up to 11 years) human trial data and samples.

Alzheimer Europe is co-leading the work on PI and communication. Alzheimer Europe was represented in this project by Cindy Birck, Sarah Campill and Ana Diaz.



Online meeting of the Multi-MeMo Advisory Board, 20 March 2025

In 2025, they:

- took part in the online general assembly meeting on 31 March,
- maintained the website and social media channels,
- developed and released the second Multi-MeMo newsletter,
- contributed to the efficient communication of the project via the Alzheimer Europe website and newsletter,
- featured Multi-MeMo in the Brain Health Supplement (October 2025),
- published a paper in Aging Clinical and Experimental Research entitled “This also matters to me: what does adherence to dementia risk reduction interventions mean to members of the public?”
- organised several consultations with the members of the Multi-MeMo Advisory Board.

Pattern-Cog



Pattern-Cog convened its final General Assembly meeting online, 13 May 2025

Pattern-Cog stands for “Personalised ageing pattern for early risk detection and prevention of cognitive impairment and dementia in cognitively healthy individuals”. Funded by ERA PerMed, the three-year project started in June 2022 and included six partners from five European countries. The overarching goal of the project was to improve dementia



prevention strategies by developing support tools for the detection of the earliest signs of impending cognitive decline which would allow early and personalised multidomain interventions.

Alzheimer Europe was co-leading the work on PI and communication. Alzheimer Europe was represented in this project by Cindy Birck and Soraya Moradi-Bachiller.

In 2025, they:

- took part in the project General Assembly meeting (online) on 13 May
- participated in the online Executive Board Management meeting
- coordinated the regular maintenance of the project's communication tools (i.e. website, Twitter & LinkedIn)
- developed and published the final project's newsletter
- featured Pattern-Cog in an article in the Dementia in Europe Magazine
- contributed to the efficient communication of the project via the Alzheimer Europe website and newsletter.

PREDICT-FTD



PREDICTFTD project kick-off meeting, Rotterdam (Netherlands), 1 March 2025

The PREDICTFTD project aims to transform the early diagnosis of frontotemporal dementia (FTD) by validating a set of liquid biomarkers and developing an AI-driven diagnostic tool. By combining data from 11 diverse cohorts, the project will implement a two-stage validation strategy to address critical challenges in distinguishing sporadic FTD from other disorders, detecting pathological subtypes and identifying the earliest changes in the presymptomatic phase of the disease. Ultimately, PREDICTFTD seeks to improve patient care, inform treatment decisions and support clinical trial recruitment. The project, which is funded for a period of 4.5 years through the Horizon Europe programme (2024-2029) brings together a consortium of 15 partners from various institutions across Europe, including leading neurologists, data scientists, health economists.



Alzheimer Europe is leading the work on PI, stakeholder engagement, and social and ethical implications, also supporting the project's communication activities. Alzheimer Europe was represented in the project by Angela Bradshaw and Soraya Moradi-Bachiller.

In 2025, they:

- took part in one General Assembly meeting on 23-24 January in Rotterdam
- set up the Public Involvement Board for this project
- organised and facilitated several online meetings with the PREDICTFTD Public Involvement Board on 19 March, 10 April and 14 October
- published an article introducing the PREDICTFTD project in the Dementia in Europe magazine, as well as several Alzheimer Europe newsletter articles on project activities.

PREDICTOM



PREDICTOM Annual Consortium Meeting, Thessaloniki (Greece), 22 October 2025

The PREDICTOM (Prediction of Alzheimer's disease using an AI driven screening platform) project, funded through IHI, saw its official start on 1 November 2023.

The goal of the PREDICTOM project is to develop a screening platform capable of identifying people at risk of dementia, before the first symptoms appear. Crucially, patients would be able to start the screening process from the comfort of their own homes. They could collect samples of bodily fluids and use digital technologies to gather results (e.g. smartphone-based eye tracking and cognitive tests).

Samples will be sent to the PREDICTOM partners' laboratories, and then to the PREDICTOM platform for processing of the data. Algorithms based on artificial intelligence would then assess the person's risk of developing dementia and their prognosis. In this way, the platform will facilitate the early diagnosis of a wider range of people, enabling earlier intervention and hopefully slowing progress of the disease.




Alzheimer Europe is leading the work on PI and social and ethical implications. Alzheimer Europe was represented in this project by Sarah Campill and Dianne Gove.

In 2025, they:

- participated in General Assembly meeting in Thessaloniki, Greece on 22-23 September
- joined regular work package and project management board meetings (online)
- contributed to the population of the official project website (e.g. project tracker webpage)
- contributed to the efficient communication of the project via the Alzheimer Europe website and social media platforms, newsletter and events
- conducted several consultations with an Advisory Board composed of lay people (e.g. older people with an interest in brain health and carers of people with dementia)
- invited members of AE's Public Involvement Pool (i.e. an online network of people with an interest in brain health, with mild cognitive impairment and people affected by dementia) to provide feedback in writing or via surveys and to invite them to join the online consultations
- conducted a literature review on ethical issues related to screening, decision making and the use of AI in the context of cognitive decline and dementia.

PROMINENT



PROMINENT online consortium meeting, 21 November 2025

PROMINENT (Precision medicine platform in neurodegenerative disease) is a collaborative pan-European public-private partnership funded through the Innovative Health Initiative (IHI) for five years that started in June 2023. PROMINENT will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities. The overriding objective is to assist clinicians with individualised decision support in the evaluation of patients with suspected cognitive impairment.



Alzheimer Europe is leading the work on PI, stakeholder mapping and engagement as well as on communication and dissemination. Alzheimer Europe was represented in this project by Ana Diaz, Dianne Gove, Angela Bradshaw and Christophe Bintener.

In 2025, they:

- took part in the project General Assembly meeting (Stockholm, Sweden and online) on 21 November
- represented Alzheimer Europe in the monthly WP1 telephone conference and contributed to the publication of a review of multimodal Alzheimer's disease prediction models
- organised and moderated WP5 calls
- organised the Public Involvement activities of the project
- maintained the project website, brand identity & social media channels through regular updates, including early career researcher interviews
- contributed to the efficient communication outreach and awareness raising activities of the project via Alzheimer Europe's Dementia in Europe Magazine, website, newsletter and events
- Monitored the submission of required reports of the External Ethics Advisor, also drafting and finalising a deliverable report on stakeholder engagement in PROMINENT.

Support of European research activities

In addition to the projects described above where Alzheimer Europe is a full partner, the organisation also supported a number of other European research projects.

EPAD

The European Prevention of Alzheimer's dementia (EPAD) initiative was a collaborative research effort to improve the chance of successfully preventing Alzheimer's dementia and to better understand early aspects of Alzheimer's disease before dementia develops. The project came to an end in September 2020 with the end of the IMI funding. An EPAD donation was given to Alzheimer Europe by Gates Ventures in 2024 for the maintenance of the website and the support of communication activities.

Alzheimer Europe was represented by Cindy Birck in this project. In 2025, she:

- coordinated the regular maintenance of the communication and dissemination tools (i.e. website, social media channels)
- contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events.



HOMEDEM

“HOMEDEM – Co-designing a Home with Dementia” is a Marie Skłodowska-Curie Actions Doctoral Network providing high-level training in design and dementia caregiving to a new generation of early-stage researchers. It is composed of 8 doctoral candidates from European higher education and research institutions from five countries: Belgium, the Netherlands, Ireland, Italy and Portugal. Each entity brings a unique expertise in dementia care, design, technology, gerontology, psychology and health economics fostering cross-disciplinary collaboration. It aims at improving the living environment of people with dementia and carers by 1. responding to changing relationships in daily life, including care dyads, 2. responding in changing needs in the living environment of people with dementia and carers, and 3. designing for responsive and sustainable care ecosystems. The project started on 1 October 2022 and will end on 30 September 2026.

Alzheimer Europe (AE) is leading the work on PI in this project by supporting the 8 doctoral researchers to gather feedback from Alzheimer Europe’s European Working Group of People with Dementia (EWG-PWD), and European Dementia Carers Working Group (EDCWG). AE is also involved in training activities for the project. AE was represented by Ana Diaz and Dianne Gove in this project.

In 2025, they:

- organised an in-person meeting for HOMEDEM with members of the EWG-PWD in Bologna on 29 September 2025
- supported the doctoral candidates in organising the above meeting and preparing the necessary pre-reading material for members of the EWG-PWD.

PANEUcare

The PANEUcare project aims to improve dementia care services across Europe, with a particular focus on underrepresented regions in Central and Eastern Europe. The PANEUcare working group seeks to address the significant disparities in how dementia is managed between Western and Northern Europe compared to Central and Eastern Europe. By bringing together researchers, people with dementia and their carers, the PANEUcare project will identify specific needs, share effective practices, and develop actionable recommendations.

Alzheimer Europe was represented by Soraya Moradi-Bachiller in this project.

In 2025, she:

- participated in the General Assembly meeting on 6-7 March in Berlin
- contributed to the development of the PANEUcare position paper.



PanEUcare

REBALANCE

The REBALANCE project is exploring a new non-invasive way to treat Alzheimer’s disease using a technique called focused ultrasound (FUS). FUS is a special type of sound wave that can be directed very precisely at specific parts of the brain without needing surgery. The project’s goal is to see if these sound waves can help clear out harmful substances in the brain that are linked to Alzheimer’s and improve brain function as well as slow down the disease progression. The research project includes both animals (e.g. rats or mice) and human-based models to understand how this technique works and how it can be safely used in people. The project also addresses ethical challenges and involves patient organizations in the dialogue to ensure efficient clinical translation of the finding that the research is ethical and that the findings can be effectively translated into real-world treatments.

Alzheimer Europe contributed to the Public Involvement and dissemination activities of REBALANCE. Alzheimer Europe was represented by Sarah Campill.

In 2025, she:

- took part in the project’s contributed to a workshop in Latvia on 25 February
- contributes to the Public Involvement activities of the project, including the development of participant-facing materials
- contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events
- featured REBALANCE during a conference symposium at the 35th Alzheimer Europe Conference in Bologna, Italy.

REMOTE-AD

The REMOTE-AD project aims to improve the necessary framework and standards for the future clinical implementation of remote digital assessments in early Alzheimer’s disease. The project also aims to evaluate the associated social and ethical risks of the use of remote digital assessment technologies from a patient and carer/supporter perspective.

Alzheimer Europe was represented by Soraya Moradi-Bachiller in this project.

In 2025, she:

- participated in the General Assembly meeting on 25-26 September in Berlin,
- contributed to the development of a report on remote digital assessments in research and routine clinical practice.

REBALANCE



TEF-Health

TEF-Health is one of four sector-specific testing facilities co-financed by the European Commission under its Digital Europe Programme. The project aims to develop a reference testing and experimentation facility for AI and robotics-based solutions in the healthcare sector. Led by Charité University Hospital in Berlin, the project has three objectives: to conduct tests and experiments in real or realistic environments, implement evaluation activities that facilitate market access for trustworthy intelligent technologies, and optimise investments by capitalising on past investments. While TEF-Health generally supports a broad range of healthcare AI and robotics use cases, brain health is one focus area, besides cancer, cardiovascular and intensive care.

Alzheimer Europe contributed to the Public Involvement, stakeholder engagement and communication activities in TEF-Health. Alzheimer Europe was represented by Dianne Gove and Angela Bradshaw.

In 2025, they:

- Co-moderated a session at a data sharing workshop organised by TEF-Health partners in Brussels, Belgium on 21 March
- Co-organised an Alzheimer Europe Bologna, Italy (October)
- Published an article on TEF-Health in the Dementia in Europe magazine (October)
- Contributed to a TEF-Health deliverable entitled “Patient and Public Advisory Group” (December)
- Hosted TEF-Health lead, Petra Ritter, at an Alzheimer Europe lunch debate in Brussels, Belgium (December).



Corporate affairs

European Parliament lunch debates and workshops

Alzheimer Europe organised two lunch debates in the European Parliament in 2025:

- On 3 June, Sirpa Pietikäinen, MEP (Finland), Romana Jerković, MEP (Croatia) and Hilde Vautmans, MEP (Belgium) co-hosted a lunch debate entitled “Preparing for new Alzheimer’s treatments in Europe”
- On 2 December, Tilly Metz, MEP (Luxembourg) and Sirpa Pietikäinen, MEP (Finland) co-hosted a lunch debate entitled “The future of dementia research in Europe”

Amongst the speakers were:

- Sebastiaan Engelborghs, Co-Chairperson of the European Alzheimer’s Disease Consortium, Vrije Universiteit Brussel, Brussels, Belgium
- Kasia Jurczak, Head of Unit “Combatting Diseases” at DG Research and Innovation, European Commission
- Miia Kivipelto, Coordinator of the AD-RIDDLE project, University of Eastern Finland, Kuopio, Finland
- Linus Jönsson, Coordinator of the PROMINENT project, Karolinska Institutet, Stockholm, Sweden
- Saila Rinne, Head of Unit “eHealth, Well-being & Ageing” at DG CNECT, European Commission
- Petra Ritter, Coordinator of the eBRAIN-Health and TEF-Health projects, Charité, Berlin, Germany
- Stefan Schreck, Adviser for Stakeholder Relations at DG Health and Food Safety, European Commission

Both events were well attended, with representatives from the European Parliament and Commission, people with dementia and their carers, Alzheimer Europe member associations, national government officials and the organisation’s sponsors.

Dementia in Europe magazine

In 2025, Alzheimer Europe published three issues of the Dementia in Europe magazine, which covered Alzheimer Europe’s activities, such as lunch debates, Alzheimer’s Association Academies, and the organisation’s involvement in various EU projects, as well as developments at a European and national level which had relevance for dementia policy. All editions were printed and mailed, as well as distributed in PDF format.

Over the three editions of the magazine, the organisation was pleased to have interviews and contributions from a number of European and national policymakers, including:

- Attila Beneda, Deputy State Secretary for Family Affairs, Hungary
- Nina Carberry MEP (EPP, Ireland)
- Lucie Davoine, Acting Head of Unit for Disability in the Directorate-General for Justice and Consumers (DG JUST)
- Romana Jerković MEP (S&D, Croatia)
- Hadja Lahbib, European Commissioner for Humanitarian Aid and Crisis Management
- Lisa Katharina Mayer, Health Expert at the Austrian National Public Health Institute
- Tilly Metz MEP (Greens/EFA, Luxembourg)
- Roxana Mînzatu, European Commission Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness
- Nathalie Moll, Secretary General, EFPIA
- Sirpa Pietikäinen MEP (EPP, Finland)
- Vladimir Prebilič MEP (Greens/EFA, Slovenia)
- Orazio Schillaci, Minister of Health, Italy
- Katrin Seeher, Mental Health Specialist, World Health Organization (WHO)
- Anna Tenje, Minister for Older People and Social Security, Sweden


- Olivér Várhelyi, Commissioner for Health and Animal Welfare
- Hilde Vautmans MEP (Renew Europe, Belgium)
- Ekaterina Zaharieva, Commissioner for Startups, Research and Innovation
- Dainius Žalimas MEP (Renew Europe, Lithuania)

The 2025 issues also included articles on a range of policy and research initiatives, meetings and publications, covering topics such as:

- “5IronmansBeatAlzheimers” campaign
- Advancing personalised dementia prevention in Europe
- Anti-Stigma initiatives
- Art and dementia
- Artificial Intelligence in dementia care and research
- Austria’s Dementia Report 2025
- Brain health campaign “Yo Me Celebro” (“I celebrate myself”)
- Clinical decision support systems (CDSS) in dementia care
- Dementia risk reduction
- Diversity and reduced inequity in dementia research, care, and policy
- EU4Health Civil Society Alliance campaign for sustainable funding
- EU disability policies
- EU evaluation by the CRPD Committee
- EU general pharmaceutical legislation
- EU Joint Action addressing Dementia and Health (JADE Health)
- European Alzheimer’s Alliance
- European Day of Persons with Disabilities

- European Group of Governmental Experts on Dementia
- European Parliament “Dementia Day”
- Health Technology Assessment
- “Human Forever” documentary film
- Hungarian dementia strategy in development
- Independent living and housing
- Lecanemab approval in Europe
- “Les Esprits Libres” French documentary film about dementia care
- “Lost Lear” theatre play about dementia in Ireland
- Organisation for Economic Cooperation and Development (OECD) “Care Needed: Improving the Lives of People with Dementia” report updated
- Preparing for new Alzheimer’s treatments in Europe
- Research into earlier Alzheimer’s diagnosis
- Sweden’s second national dementia strategy
- WHO Global Action Plan on the Public Health Response to Dementia until 2031.
- UK “Dementia Trials Accelerator”
- Ukrainian charity “Nezabutni” supporting people with dementia
- “Urge to Act” EU continence care campaign

A special supplement dedicated to the 34th Alzheimer Europe Conference was published with issue 47 of the magazine in February, a special AI-Mind project supplement was published together with Dementia in Europe issue 48 in June, and a special Brain Health supplement was published with Dementia in Europe issue 49, in October.



Snapshots from European Parliament lunch debates



Discussions between delegates (3 June 2025)



Lunch debate of 3 June 2025



Three MEPs jointly hosted the session of 3 June: (Ltr: Hilde Vautmans (Belgium), Romana Jerković (Croatia), Sirpa Pietikäinen (Finland))



Petra Ritter, speaker (2 December 2025)



Saila Rinne, speaker (2 December 2025)



Stefan Schreck, speaker (2 December 2025)



Kasia Jurczak, speaker (2 December 2025)



Representatives from The Alzheimer Society of Ireland with Irish MEP Nina Carberry, 3 June 2025



Discussions between delegates (2 December 2025)



Speakers at our European Parliament Lunch Debate (left to right: Sebastiaan Engelborghs, Miia Kivipelto, Linus Jönsson), Brussels (Belgium), 3 June 2025

Clinical Trials Watch

In 2025, Alzheimer Europe continued with the development of its Clinical Trials Watch which provides accessible and up-to-date information on clinical trials that are investigating interventions for AD and other types of dementia. As in previous years, Alzheimer Europe focused on phase II and III clinical trials that were:

- Recruiting participants and
- Conducted in at least one European country.

By the end of 2025, the following 22 phase II trials, 12 phase III clinical trials and three non-drug trials recruiting participants in Europe were included on the AE website:

Members of the EWGPWD and of the EDCWG are involved in this work. One member of the EWGPWD and three members of the EDCWG, reviewed and provided feedback on the new trials included in the Clinical Trials Watch to ensure that the information provided is understandable to lay people, both with and without a diagnosis of dementia.

Phase II trials				
Company	Study	Drug candidate	Population	Target
AC Immune	ABATE	ACI-24.060	Prodromal Alzheimer's disease	Amyloid-related (Immunotherapy)
Medical University of Lodz	Alzheimer - FuDiMe	Dimethyl fumarate	Mild cognitive impairment and dementia due to Alzheimer's disease	Inflammation (small molecule)
HelseFonna	ANeED	Ambroxol	Prodromal and early dementia with Lewy bodies	Inflammation (small molecule)
Aviadobio	ASPIRE-AD	AVB-101	Frontotemporal dementia	Other (DNA/RNA-based)
Rutgers	COMMETS	Combination Insulin and Semaglutide	Older adults with metabolic syndrome and Mild Cognitive Impairment (MCI)	Inflammation + metabolism
Denali Therapeutics	DNL593	DNL593	Frontotemporal Dementia	Other
Norwegian University of Science and Technology	ExPlas	ExPlas	Early Alzheimer's Disease	Plasma transfusion
Helse Stavanger	FEAD	Fasudil hydrochloride	Early Alzheimer's disease	Vasculature
Centre Hospitalier St Anne	IL-AD2	IL-2 (PROLEUKIN ®)	Early Alzheimer's Disease	Immunotherapy
Intra-Cellular Therapies	ITI-1284-101	ITI-1284	Agitation associated with Alzheimer's disease	Small Molecule (other Neurotransmitter)
Intra-Cellular Therapies	ITI-1284-201	ITI-1284	Psychosis associated with Alzheimer's disease	Small Molecule (other Neurotransmitter)
Imperial College London	MET-FINGER	/	At risk of developing Alzheimer's dementia	Multidomain intervention
Merck	MK-1167-008	MK-1167	Mild to Moderate Alzheimer's disease dementia	α7 nicotinic acetylcholine receptor
Merck	MK-2214-004	MK-2214	Early Alzheimer's disease	Immunotherapy (Tau)
NSC - Therapeutics GmbH	NSC001	NSC001	Mild to Moderate Alzheimer's disease dementia	Small molecule
Arctic Therapeutics	NPI-001	NPI-001	MCI or mild dementia due to Alzheimer's disease	Small molecule (antioxidant)
University of Dublin, Trinity College	NITEGSON	/	Amnesic Mild Cognitive Impairment	Electrical stimulation
Prevail Therapeutics	PROCLAIM	LY3884963	Frontotemporal Dementia	DNA/RNA-based
Janssen	Retain	JNJ-64042056	Preclinical Alzheimer's disease	Immunotherapy (Tau)
NeuroSence Therapeutics	RoAD	PrimeC	Mild to moderate Alzheimer's disease	Inflammation
NeuroTherapia	SSPN-AD	NTRX-07	Mild Cognitive Impairment or Mild to Moderate Alzheimer's disease	Inflammation
Novartis	VHB937	VHB937	Early Alzheimer's disease	Amyloid-related (immunotherapy)

Phase III trials				
Company	Study	Drug candidate	Population	Target
Acadia	ACP-204-2026	ACP-204	Alzheimer's disease psychosis	Small Molecule (Neurotransmitter receptors)
Karuna Therapeutics	ADEPT-1	KarXT	Psychosis associated with AD dementia	Small Molecule (Neurotransmitter receptors)
Karuna Therapeutics	ADEPT-4	KarXT	Psychosis associated with AD dementia	Small Molecule (Neurotransmitter receptors)
Centre regional hospitalier de Lille	CAFCA	Caffeine	Alzheimer's disease at beginning to moderate stages	/
Assistance publique – Hôpitaux de Paris	CHOLINE-2	Donepezil	Early onset AD	Small Molecule - Cholinergic System
ScandiBio Therapeutics	COGNIS	CMA2	Alzheimer's disease	Dietary supplementation
Santa Lucia	DOPAD-3	Rotigotine	Mild to moderate Alzheimer's disease	Small Molecule (other Neurotransmitter)
Suven Life Sciences Limited	Masupirdine	Masupirdine	Agitation in people with dementia	Small Molecule (other Neurotransmitter)
Eli Lilly	TRAILRUNNER-ALZ 3	Remternetug	Early Alzheimer's disease	Amyloid related (immunotherapy)
Roche	TRAVELLER	N/A – pre-screening study to identify people who are best suited to participate in one of Roche's Alzheimer's disease clinical studies		
Roche	TRONTIER 1	Trontinemab	Early symptomatic Alzheimer's disease	Amyloid-related (Immunotherapy)
Roche	TRONTIER 2	Trontinemab	Early symptomatic Alzheimer's disease	Amyloid-related (Immunotherapy)

Non-drug trials				
Company	Study	Population	Target	
Kuopio University Hospital	Gamma tACS	Dementia with Lewy Bodies, Alzheimer's disease, Frontotemporal dementia	Brain Stimulation	
University of West Attica	Mental Imagery	Early dementia	Mental Imagery	
Maastricht University	LIGHT	Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) at risk of dementia	Lifestyle Intervention	

Research participation and data sharing

In 2025, Alzheimer Europe continued to work on the Gates Ventures-funded project on research participation and data sharing.

As part of this project, the organisation completed a scoping review on barriers and enablers to participation in dementia research, which was submitted to the Journal of Prevention of Alzheimer's Disease in September 2025.

Based on the findings of this review, and with input from the EWGPWD, the EDCWG, and national member organisations, Alzheimer Europe conducted a multinational survey assessing attitudes toward research participation and data sharing across European countries. This survey was available throughout Europe in 13 languages. Findings from the survey were presented during a special symposium organised by the project at Alzheimer Europe's annual conference in Bologna. The symposium also included reflections on research participation and data sharing from a member of the European Dementia Carers Working Group, as well as from researchers and representatives of Gates Ventures.

Within the scope of the project, Alzheimer Europe conducted several focus groups with people living with dementia and carers, gathering perspectives on participating in research and the sharing of resulting data. Finally, the organisation carried out stakeholder interviews with researchers, clinicians, funders, and regulators.

Alzheimer Europe has finalised a report presenting these activities, along with a set of recommendations based on them.

Other corporate activities

Alzheimer Europe also involved people with dementia, carers and/or representatives of national associations in consultation meetings with pharmaceutical companies Anavex, BMS, Johnson & Johnson, Roche and UCB on ongoing research activities and clinical trials.

Finally, Alzheimer Europe participated in meetings of the Patient think-tank of the European Federation of Pharmaceutical Industries and Associations and collaborated with PAVE, Project Alzheimer's Value in Europe.

Organisational changes

In 2025, Alzheimer Europe also made some organisational changes including the adoption of a new Strategic Plan (2026-2030) and changes to the staff of the organisation.

New Strategic Plan (2026-2030)

In 2025, Alzheimer Europe performed a survey of satisfaction of Alzheimer Europe members with the 2021-2025 strategic plan asking them about their expectations for future strategic priorities to inform the development of new strategic plan (2026- 2030).

Based on the results of this survey, as well as discussions with the Board and members of Alzheimer Europe, Alzheimer Europe proposed a new strategic plan for 2026-2030, which includes the following 10 strategic objectives that span “changing perceptions”, “changing policy”, “changing practice” and “organisational priorities”:

1. Meaningfully involve people affected by dementia
2. Challenge stigma and promote public awareness of dementia
3. Advance the human rights of people affected by dementia
4. Champion diversity, inclusion and intersectionality
5. Make dementia a priority of European and national policies on disability, health, social affairs and research
6. Foster dementia research and innovation
7. Promote equal access to quality diagnosis, treatment, care and support
8. Raise awareness of brain health and prevention
9. Support national Alzheimer’s associations and build a strong united movement
10. Ensure financial and organisational sustainability

The new strategic plan was approved unanimously at the November 2025 AGM.

Staff changes

A number of staff changes happened in 2025, due to staff members retiring or finding employment with other organisations. Special thanks are due to Gwladys Guillory and Stefanie Peulen for their many years of services as Conference Coordinator and Finance Officer respectively.

In 2025, Alzheimer Europe welcomed the following new permanent staff members:

- In April, Isabelle Collot joined the team as a Conference Coordinator and Margarita Reyes as Communications Officer
- In September, Faye Forsyth started work as a Public Involvement Officer in replacement of Sébastien Libert who left Alzheimer Europe at the end of July

The Board of Alzheimer Europe also approved a reorganisation of the staff by creating three teams:

- The Executive, Operations, Communication and Policy Team under the Executive Director Jean Georges
- The Public Involvement and Ethics Team under the Director for Public Involvement and Ethics Dianne Gove and the Public Involvement Lead Ana Diaz
- The Research Team under the Director for Research Angela Bradshaw.

Annex 1: Meetings and conferences

Meetings organised by Alzheimer Europe (AE) in the framework of the 2025 Operating Grant

Date	Topic	Venue
28/01/2025	Alzheimer's Association Academy on "Engaging in health technology assessment and pricing and reimbursement processes"	Online
24/02/2025	AE Board Meeting	Online
24-25/03/2025	AE Board Meeting	Senningerberg, Luxembourg
25-27/03/2025	European Working Group of People with Dementia	Senningerberg, Luxembourg
22/04/2025	Alzheimer's Association Academy on "Technology in dementia care: challenges and opportunities"	Online
02/06/2025	AE Board Meeting	Brussels, Belgium
03/06/2025	Public Affairs Meeting	Brussels, Belgium
03-04/06/2025	European Dementia Carers Working Group	Brussels, Belgium
04/06/2025	Annual General Meeting	Brussels, Belgium
12/06/2025	European Working Group of People with Dementia	Online
24/06/2025	Alzheimer's Association Academy on "Mild Cognitive Impairment: terminology, support and services"	Online
02/07/2025	European Dementia Carers Working Group	Online
15/07/2025	Alzheimer's Association Academy on "Awareness campaigns"	Online
16/09/2025	Alzheimer's Association Academy on "Working with parliamentarians and interest groups"	Online
03/09/2025	European Working Group of People with Dementia and European Dementia Carers Working Group	Online
08/09/2025	European Working Group of People with Dementia	Online
29/09/2025	AE Board Meeting	Online
05-06/10/2025	European Working Group of People with Dementia	Bologna, Italy
05-06/10/2025	European Dementia Carers Working Group	Bologna, Italy
05-06/10/2025	European Group of Governmental Experts on Dementia	Bologna, Italy
10/11/2025	European Working Group of People with Dementia and European Dementia Carers Working Group	Online
11/11/2025	European Group of Governmental Experts on Dementia	Online
18/11/2025	Alzheimer's Association Academy on "Involving underrepresented groups in research"	Online
24/11/2025	Annual General Meeting	Online
25/11/2025	European Working Group of People with Dementia and European Dementia Carers Working Group	Online
27/11/2025	European Dementia Carers Working Group	Online
01/12/2025	AE Board meeting	Brussels, Belgium
02-03/12/2025	Public Affairs meeting	Brussels, Belgium
09/12/2025	Alzheimer's Association Academy on "Transport and access to cultural life, recreation, leisure and sport"	Brussels, Belgium

Date	Meeting	Venue
13 January	Meeting with WHO Europe	online
18 January	EDF's strategy development	online
25 January	EDF's ENGO meeting	online
25-26 January	EMA Clinical Trials Data Analytics Workshop	Amsterdam, Netherlands

Other meetings organised by Alzheimer Europe

Date	Topic	Venue
03/03/2025	Alzheimer Europe Foundation Board	Online
20/03/2025	Research update meeting with BMS	Online
20/03/2025	Research update meeting with Anavex	Online
03/06/2025	Company round table	Brussels, Belgium
03/06/2025	European Parliament lunch debate on "Preparing for new Alzheimer's treatments in Europe"	Brussels, Belgium
06-08/10/2025	35 th Alzheimer Europe Conference "Connecting science and communities: the future of dementia care"	Bologna, Italy
02/12/2025	Company Round Table	Brussels, Belgium
02/12/2025	European Parliament lunch debate on "The future of dementia research in Europe"	Brussels, Belgium
02/12/2025	Anti-Stigma Award Ceremony	Brussels, Belgium

EU project meetings

Date	Topic	Venue
13-14/01/2025	ADIS General Assembly	Online
15-16/01/2025	AI4Hope General Assembly	Bonn, Germany
20/01/2025	PREDICTOM Patient Advisory Group	Online
23-24/01/2025	PREDICTFTD Kick-off meeting	Rotterdam, Netherlands
29/01/2025	Pattern-Cog Executive Board	Online
04/02/2025	FluIDx-AD Kick-off meeting	Online
06/02/2025	ADIS Advisory Board and Young Adults Advisory Board	Barcelona, Spain
13/02/2025	Networking meeting for FluIDx-AD, PREDICTFTD, VOLABIOS and VAMPIRE projects	Online
14/02/2025	AD-RIDDLE Steering Committee meeting	Online
25/02/2025	REBALANCE workshop on "Patient and Public Involvement in Translational Research"	Riga, Latvia
26/02/2025	AI4Hope meeting on palliative care and dementia	Online
27-28/02/2025	DORIAN GRAY kick-off meeting	Brescia, Italy
06-07/03/2025	PANEUCARE consortium meeting	Berlin, Germany
11/03/2025	RECOGNISED final review meeting	Online
12/03/2025	PREDICTOM Public Ambassador Group meeting	Online
14/03/2025	LETHE Webinar on "How can public involvement support research on dementia risk reduction"	Online
17/03/2025	eBRAIN-Health interim review meeting	Online
20/03/2025	Multi-Memo Advisory Board meeting	Online
27/03/2025	AD-RIDDLE consultation with AE member organisations	Online
31/03/2025	Multi-Memo General Assembly	Online
03/04/2025	AD-RIDDLE Steering Committee	Online

10/04/2025	PREDICTFTD Public Involvement Board	Online
30/04/2025	DORIAN GRAY General Assembly	Online
05-07/05/2025	AI-Mind General Assembly	Bøde, Norway
13/05/2025	MinD network meeting	Online
13/05/2025	Pattern-Cog General Assembly	Online
19-20/05/2025	JPND DIGDEM project meeting	Stavanger, Norway
22/05/2025	AI-Mind review meeting	Online
26/05/2025	DORIAN GRAY Public Involvement Board	Online
28/05/2025	AI4Hope pre-event at 9 th World Congress of the European Association for Palliative Care	Helsinki, Finland
09/06/2025	EPND sustainability meeting	London, United Kingdom
10/06/2025	DORIAN GRAY Public Involvement Board	Online
10-11/06/2025	AD-RIDDLE General Assembly	London, United Kingdom
19/06/2025	PREDICTOM Public Ambassador Group meeting	Online
25/06/2025	AD-RIDDLE Advisory Board	Online
25-26/06/2025	ADIS Final Symposium	St. Augustin, Germany
27/08/2025	DORIAN GRAY Public Involvement Board	Online
01/09/2025	DORIAN GRAY Public Involvement Board	Online
04/09/2025	DORIAN GRAY General Assembly	Online
22-23/09/2025	PREDICTOM General Assembly	Thessaloniki, Greece
25/09/2025	Multi-MeMo Advisory Board	Online
25-26/09/2025	REMOTE-AD Consortium meeting	Berlin, Germany
06-07/10/2025	EPND General Assembly	Brussels, Belgium
07/10/2025	MenoBrain Doctoral Network Kick-off meeting	Bologna, Italy
09/10/2025	FluIDx-AD General Assembly	Bologna, Italy
15/10/2025	PROMINENT Midterm review meeting	Online
17/11/2025	COMMUTE Panel on “Artificial intelligence-driven predictive medicine in Alzheimer’s and Parkinson’s disease”	Luxembourg, Luxembourg
21/11/2025	PROMINENT General Assembly	Online
26/11/2025	FluIDx-AD Advisory Group	Online
27/11/2025	Multi-MeMo Advisory Board	Online
02/12/2025	DORIAN GRAY Public Involvement Board	Online
15-16/12/2025	AI-Mind General Assembly	Rome, Italy

Other meetings

Date	Topic	Venue
10/01/2025	Management Group of Dementia Panel of European Academy of Neurology (EAN)	Online
14/01/2025	ALDE Roundtable on “Clinical Trials in Europe”	Brussels, Belgium
16/01/2025	Meeting with Essity	Online
16/01/2025	Coordination Meeting of JADE (Joint Action on Dementia)	Online
16/01/2025	Meeting with Fourtold	Online
16/01/2025	WHO meeting on European Programme of Work	Online
20/01/2025	Meeting with Lilly	Online
20/01/2025	One Neurology Meeting	Online

22/01/2025	Meeting with Roche	Online
22/01/2025	Meeting with Biogen	Online
22/01/2025	WHO Europe meeting on non-communicable diseases	Online
22/01/2025	Meeting with Springer Healthcare	Online
22/01/2025	Meeting with BMS	Online
23/01/2025	Fundamental Rights Agency meeting on “Civic space and legal environment”	Online
23/01/2025	World Dementia Council (WDC) Virtual Dialogue on “Lessons from treatment”	Online
24/01/2025	Meeting with Anavex	Online
24/01/2025	WHO meeting on risk reduction guideline	Online
24/01/2025	WHO Civil Society Commission meeting	Online
27/01/2025	Management Group of EAN Dementia Pane	Online
28/01/2025	European Parliament meeting on the future of EU health policy	Brussels, Belgium
29/01/2025	Meeting with Gates Ventures	Online
30/01/2025	WHO Europe meeting on ageing	Online
30/01/2025	INTERDEM Task Force on prevention	Online
04/02/2025	European Federation of Pharmaceutical Industries and Associations (EFPIA) Patient think tank meeting	Online
04/02/2025	Meeting of European Alzheimer’s Disease Consortium	Online
06/02/2025	MetReal Cluster workshop on real-world data	Online
06/02/2025	European Disability Forum (EDF) European NGO meeting	Online
12/02/2025	JADE Kick-off meeting	Online
12-13/02/2025	Meeting with Roche	Basel, Switzerland
13/02/2025	European Medicines Agency (EMA) webinar on network strategy	Online
13/02/2025	EU4Health Civil Society Alliance meeting	Online
18/02/2025	Meeting with WDC	Online
18/02/2025	DG Research and Innovation meeting on mental health	Brussels, Belgium
18/02/2025	Civil Society Europe meeting on State of the Union	Online
19/02/2025	European Federation of Neurological Associations (EFNA) meeting on rare neurological diseases	Brussels, Belgium
19/02/2025	Long-term care alliance	Online
21/02/2025	WHO Europe meeting on “Health systems of the future: harnessing technology and innovation in health”	Online
25/02/2025	WHO launch meeting of European Health Report	Online
26/02/2025	WDC Virtual Advocacy Dialogue	Online
27/02/2025	INTERDEM Academy International Advisory Board	Online
28/02/2025	EAN Brain Health Mission Steering Committee	Online
04/03/2025	EIT Health workshop on “Driving innovation in health data and digital health”	Brussels, Belgium
06/03/2025	Meeting with InRAD	Online
07/03/2025	EMA webinar “Finding clinical trials with the ACT EU Trial Map”	Online
14/03/2025	DG Employment meeting on 2025 European Semester	Online
18/03/2025	Civil Society Europe meeting on a “Socially Just Europe”	Online
19/03/2025	EAN Brain Health Summit	Brussels, Belgium
21/03/2025	Innovative Health Initiative (IHI) AD Strategy Meeting	Brussels, Belgium
25/03/2025	Meeting with OIC	Senningerberg, Luxembourg
31/03/2025	WHO launch meeting of report on “Addressing dementia in refugees and migrants”	Online

ANNEX 1 2025 MEETINGS

31/03/2025	EAN Brain Health Mission Forum	Online
01/04/2025	InRad Board	Online
01-02/04/2025	EMA Patients' and Consumers' Working Party (PCWP)	Amsterdam, Netherlands
02/04/2025	Meeting with Johnson & Johnson	Online
02/04/2025	Meeting with European Public Health Alliance (EPHA)	Online
03/04/2025	European Commission Strategic Dialogue on future of ESF+	Online
03/04/2025	EPHA Policy and Advocacy Meeting	Online
04/04/2025	Meeting with Eventsforce	Online
04/04/2025	Meeting with Lilly	Online
04/04/2025	Meeting with Anavex	Online
09-10/04/2025	Conference venue study visit	Belgrade, Serbia
10-11/04/2025	European Alzheimer's Disease Consortium (EADC)	Belgrade, Serbia
11/04/2025	EDF training on disability campaigning	Online
15-16/04/2025	Conference venue study visit	Bologna, Italy
30/04/2025	Meeting with BMS	Online
02/05/2025	EMA Network Advisory Group on Raw Data	Online
05/05/2025	Meeting with Ri-scatti project	Online
07/05/2025	Meeting with Association Luxembourg Alzheimer	Senningerberg, Luxembourg
08/05/2025	EFPIA patient think tank	Online
09/05/2025	EAN Dementia Guideline Taskforce	Online
13/05/2025	Scanbalt event "New modalities in neurodegenerative disease management – is Europe ready to innovate?"	Brussels, Belgium
15/05/2025	EU4Health Civil Society Alliance meeting	Online
15-16/05/2025	Conference venue study visit	Dublin, Ireland
15-17/05/2025	8 th Venusberg meeting on neuroinflammation	Belval, Luxembourg
16/05/2025	Meeting with International Huntington Association	Online
16/05/2025	Meeting with UCB	Online
19/06/2025	EPHA General Meeting	Online
20/05/2025	JADE Health workshop on "Optimising outreach: Communication and dissemination strategies for dementia-related projects"	Online
21/05/2025	Joint Undertakings reception on public-private partnerships	Brussels, Belgium
27/05/2025	WHO meeting on ageing strategy	Online
05/06/2025	EDF NGO Coordination Meeting	Online
12/06/2025	EMA PCWP	Online
13/06/2025	Euractiv webinar on early detection and diagnosis	Online
18/06/2025	Roche meeting on clinical study recruitment	Online
21/06/2025	EAN Dementia Pane	Helsinki, Finland
21/06/2025	Meeting with EFNA	Helsinki, Finland
24/06/2025	EU-X-CT Public Stakeholder Conference	Online
24/06/2025	EAN Dementia Guideline Taskforce	Online
26/06/2025	EU4Health workshop on access to healthcare for persons with disabilities	Online
02/07/2025	Meeting with Association Luxembourg Alzheimer and CESAS	Online
02/07/2025	EMA Annual Training for patients, consumers and healthcare professionals	Amsterdam, Netherlands
02/07/2025	DG Employment webinar on persons with disabilities accessing healthcare	Online
03/07/2025	DG Employment webinar on EU anti-poverty strategy	Online

03/07/2025	EMA Network Advisory Group on Raw Data	Online
07-08/07/2025	“Mind the future” roundtable	Milan, Italy
09/07/2025	Alzheimer’s Disease International Council Meeting	Online
09/07/2025	EMA Scientific Advice Working Party	Online
14/07/2025	WHO Webinar on opportunities to engage in 75 th Regional Committee	Online
23/07/2025	DG Employment webinar on forthcoming EU Civil Society Strategy	Online
26/07/2025	Alzheimer’s Disease Data Initiative (ADD) round table on data sharing	Online
27/07/2025	ISTAART immersive workshop on “Building capacity for collaborations among researchers and people with lived experience”	Toronto, Canada
26-31/07/2025	Alzheimer’s Association International Conference (AAIC)	Toronto, Canada
30/07/2025	Amsterdam Alzheimer Centre Scientific Advisory Board	Toronto, Canada
07/08/2025	Alzheimer Europe Foundation Board	Senningerberg, Luxembourg
15/09/2025	Anti-Stigma Award Jury	Online
18/09/2025	EU4Health Civil Society Alliance meeting	Online
23-24/09/2025	EMA PCWP	Amsterdam, Netherlands
25/09/2025	SciComm Conference	Luxembourg, Luxembourg
25/09/2025	EFPIA Life Sciences Week meetings on “Facing the Alzheimer’s paradigm” and “The EU’s cardiovascular health plan”	Brussels, Belgium
26/09/2025	Meeting with CBRE Charity Board	Online
02/10/2025	EDF NGO Coordination Meeting	Online
14/10/2025	Meeting with Landesbühnen Sachsen	Online
16/10/2025	MEP Interest group on brain health and neurological conditions	Brussels, Belgium
16/10/2025	EPHA policy and advocacy meeting	Brussels, Belgium
16/10/2025	Urge to Act Alliance meeting	Online
17/10/2025	EFNA Workshop on health literacy	Brussels, Belgium
22/10/2025	Eurocarers training on “Self-care and care competences for informal caregivers”	Online
28/10/2025	Meeting with Childhood Dementia Initiative	Online
29/10/2025	Accelerating Clinical Trials in the EU (ACE EU) multi stakeholder platform	Online
29/10/2025	Meeting with GetBrainHealthy Project	Senningerberg, Luxembourg
30-31/10/2025	EADC Meeting	Edinburgh, United Kingdom
05-07/11/2025	XI CEAFA and XV Alzheimer Iberoamerica Conference	Ibiza, Spain
06/11/2025	EFPIA Patient Think Tank	Online
06-07/11/2025	13 th International Congress on Person-Centred Medicine	Reykjavik, Iceland
11-12/11/2025	European Policy Centre round table discussion on future of brain health in the era of AI	Brussels, Belgium
12-13/11/2025	9 th International Pharmaco-Economic Collaboration on Alzheimer’s Disease (IPECAD) conference	Glasgow, United Kingdom
18-19/11/2025	EMA PCWP	Amsterdam, Netherlands
20/11/2025	EU4Health Civil Society Alliance meeting	Online
24/11/2025	Meeting with Helms Briscoe	Online
26/11/2025	EDF Meeting on “Rights delayed: Air travel for passengers with disabilities”	Online
04-05/12/2025	European Day of Persons with Disabilities Conference	Brussels, Belgium
09/12/2025	European Parliament event on “Dementia and brain health in women”	Brussels, Belgium
10/12/2025	European Parliament High-Level event on Critical Medicines Act	Brussels, Belgium
15/12/2025	EMA Multi-Stakeholder workshop on patient registries for Alzheimer’s disease	Amsterdam, Netherlands

Annex 2: Scientific publications in 2025

In 2025, Alzheimer Europe staff contributed to the following scientific publications:

Alzheimer Europe (2025). *Dementia in Europe Yearbook 2025: Transport and access to cultural life, recreation, leisure and sport*. ISBN 978-2-919835-03-4, Luxembourg, Alzheimer Europe

Alzheimer Europe. (2025). *The Prevalence of Dementia in Europe 2025*. ISBN 978-2-919835-04-1, Luxembourg, Alzheimer Europe, Zenodo. DOI: 10.5281/ZENODO.18339752

Campill S, Gove D, Diaz A, (.../...) Georges J, & The PREDICTOM consortium. (2025). Informed Choices and Early Dementia Risk Disclosure in Home-Based Assessments in the PREDICTOM Study: A Public Involvement Approach. *Alzheimer's & Dementia*, 21(57), e108833. DOI: 10.1002/alz70861_108833

Diaz-Ponce A, Birck C, Bradshaw A, Georges J, Lamirel D, Moradi-Bachiller S, Gove D. (2025). Informed Consent in dementia research: how Public Involvement can contribute to addressing “old” and “new” challenges. *Frontiers in Dementia*. DOI: 10.3389/frdem.2025.1536762

Diaz-Ponce A, Campill S, Barbera M, **Birck C,** Soldevila-Domenech N et al. (2025). “This also matters to me”: What does adherence to dementia risk reduction interventions mean to members of the public? *Aging Clinical and Experimental Research*, 38(1), 32. DOI: 10.1007/s40520-025-03288-x

Dubois B, Villain N, Schneider L, Fox N, **Georges J** et al. (2025). Alzheimer disease is a clinical-biological construct: An IWG recommendation HHS Public Access. (originally published in 2024)

Duffner L, Moradi S, Diaz A, Gove D, Bradshaw A, & Georges J. (2025). Pathways to Participation – Understanding Barriers and Enablers to Participation in Dementia Research. *Alzheimer's & Dementia*, 21(57), e108736. DOI: 10.1002/alz70861_108736

Falgàs N, Maure-Blesa L, Ances B, Flores-Aguilar L, Hartley S, (.../...) **Bradshaw A** et al. (2025). Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference. *Alzheimer's & Dementia*, 21(7), e70309. DOI: 10.1002/alz.70309

Frederiksen K S, Boada M, Dubois B, Engelborghs S, Frisoni G B, **Georges J** et al. (2025). Navigating the introduction of anti-amyloid therapy in Europe: A position statement by individual members of the EADC. *Alzheimer's Research & Therapy*, 17(1), 116. DOI: 10.1186/s13195-025-01766-y

Frisoni G, Ribaldi F, Allali G, Bieth T, Brioschi Guevara AJ, (.../...) **Georges J** et al. (2025). Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities. *The Journal of Prevention of Alzheimer's Disease*. DOI: 10.1016/j.tjpad.2025.100098

Hermans AMM, Bakker E, Starokozhko V, Den Otter L, Elferink AJA, **Bradshaw A,** et al. (2025). Biomarkers for neurodegenerative diseases in

regulatory decision-making by the European Medicines Agency. *A&D Transl Res & Clin Interv*.11(1):e70072. DOI : 10.1002/trc2.70072

Soldevila-Domenech N, Ayala-Garcia A, Barbera M, Lehtisalo J, Forcano L, **Diaz-Ponce A,** et al. (2025). Adherence and intensity in multimodal lifestyle-based interventions for cognitive decline prevention: state-of-the-art and future directions. *Alz Res Therapy*. 17(1):61. DOI: 10.1186/s13195-025-01691-0

Hilberger H, Buchgraber-Schnalzer B, Huber S, Weitlaner T, Bödenler M, (.../...) **Diaz A** et al. (2025). Design of a Mobile App and a Clinical Trial Management System for Cognitive Health and Dementia Risk Reduction: User-Centered Design Approach. *JMIR Aging*, 8, e66660. DOI: 10.2196/66660

Koh W Q, Roes M, De Vugt M, Sezgin D, (.../...) **Diaz A,** et al. (2025). What are the unmet needs in people affected by dementia? A scoping review of reviews. *Aging & Mental Health*, 29(11), 1943–1966. DOI: 10.1080/13607863.2025.2534406

Lorenzini L, Tranfa M, Pieperhoff L, Masserini F, Ten Kate M, (.../...) **Birck C,** et al. (2025). Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning. *Alzheimer's & Dementia*, 21(10), e70762. DOI: 10.1002/alz.70762

Neal D, Bartels SL, Chaouni SB, Caprioli T, Comas-Herrera A, (.../...) **Diaz A** et al. (2025). Effective for whom? A review of psychological and social intervention recommendations in European dementia care guidelines, through the lenses of social health and intersectionality. *Behavioral Sciences*. 10.3390/bs15040457

Sannemann L, Rhodius-Meester HFM, Ekelund M, Van Der Flier WM, (.../...) **Georges J,** (.../...) & the PROMINENT consortium. (2025). Evaluation and Validation of a Precision Medicine Platform in Neurodegenerative Disease (PROMINENT). *Alzheimer's & Dementia*, 21(S4), e105478. DOI: 10.1002/alz70858_105478

Tsabay C, Sezgin D, Innes A, **Gove D, Diaz A,** et al. (2025). Understanding and guiding technology use in dementia: A pan-European mapping and consensus study. *Frontiers in Dementia*, 4, 1735879. DOI: 10.3389/frdem.2025.1735879

Veronese N, Soysal P, Demurtas J, Solmi M, Bruyère O (.../...) **Georges J** et al. (2025). Physical activity and exercise for the prevention and management of mild cognitive impairment and dementia: a collaborative international guideline. (ARABIC VERSION)

Xia X., **Duffner L A, Bintener C, Bradshaw A, Lamirel D.,** & Jönsson, L. (2025). Diagnostic and prognostic multimodal prediction models in Alzheimer's disease: A scoping review. *Journal of Alzheimer's Disease*. DOI: 10.1177/13872877251351630

Financial Report


Financial Report

A few words from our Honorary Treasurer



Marco Blom


I am delighted to report that, after last year’s rapid growth and record income, we were able to further increase our income by around EUR 150K or 4.3% compared to 2024. On the expenditure side, we had a modest decrease of EUR 63K or 2% compared to 2024 but still ended the year with over EUR 3 million in income and expenditure.



As can be seen from the below graph, our income from EU funding, and particularly our project funding exceeded the 2024 levels by a healthy margin. Similarly, our Annual Conference in Bologna in 2025 constituted a new record in attendance with over 1,500 delegates and a corresponding record in conference income of over half a million. We were even able to include the conference surplus of EUR 134,615 as “income received on account” to be used towards the conference costs in 2025. When it comes

to other subsidies, the significant drop can primarily be explained by the absence of the support we received in 2024 from the City of Geneva and the Geneva International Conference Centre providing the conference venue for our Annual Conference rent free.

Total income in 2024 and 2025




As can be seen from the below graph, we saw a small decrease in overall expenditure in 2025, despite the increase in staff costs from EUR 1.4 to EUR 1.6 million. This increase is linked to the growing number of AE staff dedicated to collaborating in the expanding number of EU projects the association is involved in. However, the costs for meetings including the Annual Conference in Bologna were lower than those for our Annual Conference in Geneva in 2024 and this despite having record numbers of delegates attending in 2025. Similarly, expert costs in 2025 were lower than in 2024, mainly due to the lower costs for conference staff.

with a surplus of over EUR 134K which we will use as income received on account to support our 2026 Conference. In addition, we were able to close the year with a healthy operating surplus of EUR 89,069 whilst also providing a grant of EUR 106,587 to the Alzheimer Europe Foundation making 2025 one of the most successful years in the history of the association.

It will be impossible to thank all the sponsors and partners of the association in this preface, but please check out the page with all

Total expenditure in 2024 and 2025



As the Honorary Treasurer of Alzheimer Europe, I am truly proud of last year's accounts. Alzheimer Europe was able to take on a growing number of EU projects, continue to organise a highly successful Annual Conference with over 1,500 participants and support the work and meetings of its European Working Group of People with Dementia and European Dementia Carers Working Group. Despite a very ambitious work programme, we were able to close our conference accounts

our supporters at the end of this financial report. Let me single out the Luxembourg Fondation Alzheimer though for again providing us with an incredibly generous unrestricted grant of EUR 87,000 for our activities in 2025. Last year was also the final year of our four-year framework partnership agreement with the Citizens Equalities Rights and Values (CERV) Programme of the European Union which provides support to European associations for people with disabilities



Marco Blom speaking at the 2025 AGM.

and which accounted for EUR 566,860 or 18% of our overall income making the CERV programme our biggest single contributor. I was therefore particularly happy that we learned at the end of 2025 that Alzheimer Europe was successful in its application for a new three-year framework partnership agreement under the same programme for the period of 2026-2028 thus contributing to the stable financial outlook for our finances in the years to come.

For the presentation of these accounts, my thanks go to Stefanie Peulen, our Finance Officer who retired in the middle of the year leaving our Executive Director Jean Georges to dedicate more time to the

monitoring of the financial situation and fundraising compared to previous years. In 2025, we were also successful in outsourcing our book-keeping and financial reporting to In Extenso who have been able to take over from Stefanie and produce the detailed financial reports that made it easy for my colleagues in the Board to assess and understand the financial situation of Alzheimer Europe throughout the year.

This will be the last Alzheimer Europe Financial Report that I will be presenting as the organisation's Honorary Treasurer, as I will be retiring from my positions both at Alzheimer Nederland, as well as Alzheimer Europe.

Looking back over the past six years, I am truly proud to have seen the income of Alzheimer Europe grow from EUR 1.9 million in 2019 to EUR 3.3 million in 2025. Despite the two years affected by the COVID pandemic in 2020 and 2021, the organisation was consistently able to produce a small surplus and our reserves have grown as a consequence from EUR 407K on 1 January 2019 to EUR 721K by the end of 2025. In parallel, we have been able to further develop the Alzheimer Europe Foundation which had reserves of EUR 280K in 2019 and closed last year with even healthier reserves of EUR 659K. As a result, I feel confident to leave Alzheimer Europe in a healthy financial situation with diversified and stable sources of income and I wish my successor a stable hand for the management of the organisation's finances.

Marco Blom
Honorary Treasurer
Alzheimer Europe

Report of the Réviseur d'entreprises agréé



GROUPE AUDIT LUXEMBOURG

MEMBRE DU RÉSEAU INTERNATIONAL GROUPE AUDIT

To the Board of Directors of
Alzheimer Europe
 5, Heienhaff
 L-1736 Senningerberg

REPORT OF THE RÉVISEUR D'ENTREPRISES AGRÉÉ

Opinion

We have audited the annual accounts of Alzheimer Europe (the "Association"), which comprise the balance sheet as at December 31, 2025, and the profit and loss account for the year then ended, and notes to the annual accounts, including a summary of significant accounting policies.

In our opinion, the accompanying annual accounts present fairly, in all material respects, the financial position of the Association as at December 31, 2025 and the results of its operations for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation of the annual accounts.

Basis for Opinion

We conducted our audit in accordance with the Law of July 23, 2016 on the audit profession, as amended (Law of July 23, 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the "Commission de Surveillance du Secteur Financier" (CSSF). Our responsibilities under the Law of July 23, 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the « Responsibilities of "réviseur d'entreprises agréé" for the audit of the annual accounts » section of our report. We are also independent of the Association in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the annual accounts, and have fulfilled our other ethical responsibilities under those ethical requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Board of Directors for the Annual Accounts

The Board of Directors is responsible for the preparation and fair presentation of these annual accounts in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the annual accounts, and for such internal control as the Board of Directors determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, the Board of Directors is responsible for assessing the Association's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Association or to cease operations, or has no realistic alternative but to do so.

Groupe Audit Luxembourg - cabinet de révision agréé

société à responsabilité limitée au capital de 12 500 euros • 4, rue Pierre de Coubertin L-1358 Luxembourg • LUXEMBOURG
 www.groupeaudit.lu • office : +352 24 55 88 94 • R.C.S. Luxembourg : B171737 • TVA LU25676803



Responsibilities of the “Réviseur d'Entreprises Agréé” for the Audit of the Annual Accounts

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue a report of “réviseur d'entreprises agréé” that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of July 23, 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with the Law of July 23, 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Association's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our report. However, future events or conditions may cause the Association to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Board of Directors regarding, amongst other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Luxembourg, February 23, 2026

Groupe Audit Luxembourg
Cabinet de révision agréé



Jean-Nicolas Leglise

ALZHEIMER EUROPE

Association sans but lucratif
RCS Luxembourg F2773

Balance sheet as of December 31, 2025

	Notes	2025 (Euro)	2024 (Euro)
ASSETS			
C. Fixed assets	2.2.2, 2.2.3	55 851,24	62 629,47
I. Intangible fixed assets	3	6 187,64	12 664,54
II. Tangible fixed assets	4	49 663,60	49 964,93
D. Current assets		1 693 898,85	1 742 259,35
II. Debtors	2.2.4, 5	600 245,20	346 381,71
a) becoming due and payable within one year		600 245,20	346 381,71
IV. Cash at bank and in hand		1 093 653,65	1 395 877,64
E. Prepayments and accruals	2.2.5, 6	144 715,65	32 535,57
		1 894 465,74	1 837 424,39
LIABILITIES			
A. Capital and reserves		721 316,49	632 247,51
V. Profit or loss brought forward		632 247,51	621 715,26
VI. Profit or loss for the financial year		89 068,98	10 532,25
B. Provisions	2.2.6, 7	40 205,17	60 259,05
C. Creditors	2.2.7, 8	1 002 944,08	977 384,52
a) becoming due and payable within one year		1 002 944,08	977 384,52
D. Deferred income	2.2.8, 9	130 000,00	167 533,31
		1 894 465,74	1 837 424,39

The accompanying notes are an integral part of these annual accounts.

ALZHEIMER EUROPE

Association sans but lucratif
RCS Luxembourg F2773

**Profit and loss account
Year ended December 31, 2025**

	Notes	2025 (Euro)	2024 (Euro)
4. Other operating income	2.2.9, 10	3 139 355,15	3 110 289,17
5. Raw materials and consumables and other external expenses	11	-1 315 704,40	-1 624 736,30
b) Other external expenses		-1 315 704,40	-1 624 736,30
6. Staff costs	12, 13	-1 585 883,65	-1 365 292,48
a) Wages and salaries		-1 399 231,38	-1 218 774,90
b) Social security costs		-186 652,27	-146 517,58
i) relating to pensions		-108 444,56	-99 473,60
ii) other social security costs		-78 207,71	-47 043,98
7. Value adjustments		-27 217,88	-34 164,99
a) in respect of formation expenses and of tangible and intangible fixed assets		-27 217,88	-34 164,99
8. Other operating expenses	14	-125 998,87	-92 174,33
11. Other interest receivable and similar income			
b) other interest and similar income		4 562,28	16 660,05
14. Interest payable and similar expenses			
b) other interest and similar expenses		-43,65	-48,87
		89 068,98	10 532,25

The accompanying notes are an integral part of these annual accounts.

Alzheimer Europe
Association sans but lucratif

R.C.S. LUX F2773

5 Heienhaff
L-1736 Senningerberg

NOTES TO THE ANNUAL ACCOUNTS
Annual accounts
31 December 2025

NOTE 1 - GENERAL INFORMATION

Alzheimer Europe ("the association") was established on 2 March 1992 and is organised under the laws of Luxembourg as a non profit association subject to the law of 21 April 1928, amended by the law of 4 March 1994 and of 7 August 2023 for an unlimited period. It is registered with Trade and Company Register of Luxembourg with the number F2773.

Alzheimer Europe is a voluntary organisation whose purpose is to enhance the dignity, respect and self-determination of the person with dementia and his/her family and other supporters throughout the course of the disease and to improve the quality of life, the care and treatment of people with dementia, their families and their carers through collaboration amongst its members.

Alzheimer Europe fully commits to promoting the rights of people living with dementia. These rights are universal, and guaranteed in the European Convention of Human Rights, the Universal Declaration of Human Rights, the International Covenants on Economic, Social and Cultural Rights and Civil and Political Rights, and the United Nations Convention on the Rights of Persons with Disabilities.

Alzheimer Europe affirms that every person living with dementia has:

- > The right to a timely diagnosis;
- > The right to access quality post diagnostic support;
- > The right to person-centred, coordinated, quality care throughout their life;
- > The right to equitable access to treatments and therapeutic interventions;
- > The right to be respected as an individual in their community.

Alzheimer Europe sees its mission as changing perceptions, policy and practice in order to improve the lives of people affected by dementia.

Alzheimer Europe will achieve this mission by

- > providing a voice to people with dementia and their carers
- > making dementia a European priority
- > changing perceptions and combating stigma
- > raising awareness of brain health and prevention
- > strengthening the European dementia movement and
- > supporting dementia research.

Alzheimer Europe will involve people with dementia and carers in all activities, promote dementia as a public and research priority with International, European and national institutions, organise in-person and online meetings, workshops and conferences, report on policy and scientific developments across Europe via its newsletters, magazines, reports, website and social media, support activities of national Alzheimer's associations, exchange good practices in dementia and contribute to research via its public involvement activities.

The registered office of the Association is established in L-1736 Senningerberg, 5 Heienhaff.

The Association's financial year starts on 1 January and ends on 31 December of each year.

NOTE 2 - PRINCIPLES, RULES AND VALUATION METHODS

2.1. GENERAL PRINCIPLES

The annual accounts are prepared in conformity with the Luxembourg legal and regulatory requirements and according to generally accepted accounting principles applicable in Luxembourg under the historical cost convention. The accounting policies and valuation principles are, apart from those enforced by the law, determined and implemented by the management.

The preparation of annual accounts requires the use of certain critical accounting estimates. It also requires the management to exercise its judgement in the process of applying the accounting policies. Changes in assumptions may have a significant impact on the annual accounts in the period in which the assumptions changed. The management believes that the underlying assumptions are appropriate and that the annual accounts therefore fairly present the financial position and results.

The association has voluntarily adopted the accounting policies of the amended law of 19 December 2002.

Alzheimer Europe
Association sans but lucratif

2.2. SIGNIFICANT ACCOUNTING POLICIES

The main valuation rules applied by the Company are the following:

2.2.1. Foreign currency translation

The association maintains its books, records and bank accounts in EUR. Transactions expressed in currencies other than EUR are translated at the exchange rate applied by the bank at the time of the payment. If this rate is not known at the time the accounts are established, the monetary assets and liabilities in foreign currency and the underlying revenues and expenses are valued at the exchange rate prevailing at the Balance Sheet date, and exchange gains or losses will be recorded in the Profit and Loss account at the moment of their realisation.

2.2.2. Intangible assets

Intangible fixed assets are valued at purchase price including the expenses incidental thereto or at production cost, less cumulated depreciation amounts written off and value adjustments. Except for goodwill, these value adjustments are not continued if the reasons for which they were made have ceased to apply.

The depreciation rates and methods applied are as follows:

	Depreciation rate	Depreciation method
Concessions, patents, licences and similar rights and assets	33%	Straight-line

2.2.3. Tangible assets

Tangible fixed assets are valued at purchase price including the expenses incidental thereto or at production cost. Tangible fixed assets are depreciated over their estimated useful economic lives.

The depreciation rates and methods applied are as follows:

	Depreciation rate	Depreciation method
Other fixtures and fittings, tools and equipment	33%	Straight-line
Furniture	20%	Straight-line
Computer equipment	33%	Straight-line

Lands are not depreciated.

Where the Company considers that a tangible fixed asset has suffered a durable depreciation in value, an additional write-down is recorded to reflect this loss. These value adjustments are not continued if the reasons for which they were made have ceased to apply.

2.2.4. Debtors

Debtors are valued at their nominal value. They are subject to value adjustments where their recovery is compromised. These value adjustments are not continued if the reasons for which they were made have ceased to apply.

2.2.5. Prepayments

This asset item includes expenditures incurred during the financial year but relating to a subsequent financial year.

2.2.6. Provisions

Provisions are intended to cover losses or debts, the nature of which is clearly defined and which, at the date of the balance sheet, are either likely to be incurred or certain to be incurred but uncertain as to their amount or the date on which they will arise. Provisions related to previous exercises are reviewed and reversed if they become purposeless.

2.2.7. Creditors

Creditors are recorded at their reimbursement value.

2.2.8. Deferred income

Deferred income represents amounts received or invoiced during the financial year or earlier, that will be booked to income in a subsequent financial year. The underlying transactions may have already been recognised in the profit and loss account with the unused portion being transferred to a future period (deferred funding), or may fully relate to a subsequent period when they will be booked to income (funding received on account).

2.2.9. Co-financing in kind

Goods or services obtained at reduced rates or for free are recorded at the fair market value of the item received. Expertise from member organisations is valued at a standard daily rate. In-kind contributions are booked in a separate revenue account. The expense side of the transaction is recorded in its functional expense account.

Alzheimer Europe
Association sans but lucratif

NOTE 3 - INTANGIBLE ASSETS

The movements of the year are as follows:

	2025 EUR	2024 EUR
Gross book value as at 1 January 2025	70 732,85	53 037,77
Additions for the year	-	17 695,08
Disposals for the year	-	-
Gross book value as at 31 December 2025	70 732,85	70 732,85
Accumulated value adjustment as at 1 January 2025	(58 068,31)	(43 641,41)
Additions for the year	(6 476,91)	(14 426,90)
Disposals for the year	-	-
Accumulated value adjustment as at 31 December 2025	(64 545,22)	(58 068,31)
Net book value - Opening balance	12 664,54	9 396,36
Net book value - Closing balance	6 187,63	12 664,54

NOTE 4 - TANGIBLE ASSETS

The movements of the year are as follows:

	2025 EUR	2024 EUR
Gross book value as at 1 January 2025	110 192,88	120 818,76
Additions for the year	20 439,65	54 303,74
Disposals for the year	-	64 929,62
Gross book value as at 31 December 2025	130 632,53	110 192,88
Accumulated value adjustment as at 1 January 2025	(60 227,95)	(105 419,48)
Additions for the year	(20 741,04)	(19 738,09)
Disposals for the year	-	(64 929,62)
Accumulated value adjustment as at 31 December 2025	(80 968,99)	(60 227,95)
Net book value - Opening balance	49 964,93	15 399,28
Net book value - Closing balance	49 663,54	49 964,93

NOTE 5 - DEBTORS

Debtors consist of:

	2025 EUR	2024 EUR
Accruals for EU and other public funding	409 667,10	186 295,06
Other receivables	190 878,10	160 086,65
Total	600 545,20	346 381,71

NOTE 6 - PREPAYMENTS AND ACCRUALS

Prepayments and accruals can be broken down as follows:

	2025 EUR	2024 EUR
Other accruals	4 415,65	32 535,57
Conference Costs Dublin 2026	140 300,00	0,00
Total	144 715,65	32 535,57

Alzheimer Europe
Association sans but lucratif

NOTE 7 - PROVISIONS

Provisions are composed of:

	2025 EUR	2024 EUR
Provision for untaken holidays	40 205,17	35 418,05
Audit provision (*)	0,00	10 544,63
Other debts (*)	0,00	14 296,37
Total	40 205,17	60 259,05

(*) these items have been reclassified to Note 8 creditors for the year 2025

NOTE 8 - CREDITORS

The amount due and payable for creditors are as follows:

	2025 EUR	2024 EUR
EU and other public funding received on account	744 789,64	720 202,68
Grant for Alzheimer Europe Foundation	106 586,67	0,00
Trade creditors	28 338,01	166 251,10
Social security debts	64 996,48	58 994,96
Tax debts	29 147,37	30 875,65
Audit provision	14 040,00	0,00
Other creditors	15 045,91	1 060,13
Total	1 002 944,08	977 384,52

NOTE 9 - DEFERRED INCOME

Deferred income consists of:

	2025 EUR	2024 EUR
Corporate sponsorship received on account	130 000,00	112 500,00
Deferred funding	0,00	55 033,31
Total	130 000,00	167 533,31

NOTE 10 - OTHER OPERATING INCOME

Other operating income is composed of:

	2025 EUR	2024 EUR
EU and other public funding	1 483 988,45	1 326 855,43
Project participation and other subsidies	502 786,68	756 947,34
Corporate funding (*)	470 364,99	430 360,40
AE Conference registration fees	553 015,00	266 350,00
Co-financing in kind	120 450,00	185 574,71
Deferred income	55 033,31	113 353,37
Membership fees and contributions	72 160,00	67 391,50
Donations	9 659,29	5 863,10
Other operating income	32 012,65	3 916,02
Income received on account	-160 115,22	-46 342,70
Total	3 139 355,15	3 110 289,17

(*) Corporate funding is accepted by Alzheimer Europe in line with its internal rules and regulations to ensure the independence of the association. All funders and amounts are acknowledged in full transparency on the Alzheimer Europe website and in the annual reports. Main sponsors (over 10,000 Euro) were:

	2025 EUR	2024 EUR
Hoffmann-La Roche	93 919,99	57 500,00
Lilly	90 000,00	80 000,00
Bristol Meyers Squibb	46 000,00	30 000,00
Biogen	37 500,00	27 500,00
Novo Nordisk	35 000,00	40 000,00
Eisai	35 000,00	25 000,00
C2N Diagnostics	27 500,00	22 500,00
Johnson & Johnson	25 725,00	22 700,00
Anavex	16 900,00	0,00
UCB	16 720,00	0,00
Danone/Nutricia	12 500,00	12 500,00
GE Healthcare	12 500,00	12 500,00
BioArctic	10 000,00	0,00
Merck Sharp & Dohme	10 000,00	0,00
Otsuka	0,00	15 000,00
Prothena	0,00	20 000,00
Terumo BCT	0,00	19 000,00
Other sponsors	1 100,00	46 160,40
Total	470 364,99	430 360,40

Alzheimer Europe
Association sans but lucratif

NOTE 11 - OTHER EXTERNAL EXPENSES

Other external expenses are composed of:

	2025 EUR	2024 EUR
Meeting and accomodation expenses	577 834,39	729 849,84
External experts	260 609,74	361 476,01
Office rent and associated costs	162 928,47	157 647,24
Travel expenses	83 257,34	118 437,44
Equipment and Leasing	74 837,66	115 384,18
Communication costs	64 340,28	71 442,28
Publication and Information material	67 281,66	51 822,11
Bank charges	10 293,59	7 380,88
Office stationery and related costs	4 838,75	4 674,10
Membership fees	5 475,00	3 900,00
Other costs	4 007,52	2 722,22
Total	1 315 704,40	1 624 736,30

NOTE 12 - STAFF

The association employed an average of 17 persons on a full time equivalent basis during the financial year (2024: 15), one Executive Director and 16 employees.

NOTE 13 - REMUNERATION OF THE BOARD OF DIRECTORS

No advances or loans have been granted to the members of the management during the period ending 31 December 2025.

No remuneration was paid to members of the Management Board out of the results of the financial year.

NOTE 14 - OTHER OPERATING EXPENSES

Other operating expenses can be broken down as follows:

	2025 EUR	2024 EUR
Grant to Alzheimer Europe Foundation	106 586,67	78 646,49
Software licenses	19 412,20	13 527,84
Total	125 998,87	92 174,33

NOTE 15 - OFF-BALANCE SHEET COMMITMENTS

As at December 31, 2025, the association had rental guarantees of EUR 77,067.09 granted to the owners of the office used by the association.

NOTE 16 - RELATED-PARTY TRANSACTIONS

The following significant transactions with related parties have been entered into during the year under review:

	2025 EUR	2024 EUR
Service fees and other support received from Alzheimer Europe Foundation	36 671,46	65 086,84
Grant for Alzheimer Europe Foundation	106 586,67	78 646,49
Grant from Fondation Alzheimer, Luxembourg	87 000,00	87 000,00
Membership fees and conference fees from Alzheimer Nederland	17 920,00	19 970,00
Total	248 178,13	250 703,33

NOTE 17 - SUBSEQUENT EVENT

There were no events subsequent to the financial year-end which in the opinion of the Directors may have had a material impact on these annual accounts.

**Appendices
for the financial year ended 31 December, 2025**

1°) 1 - Number of members per tranche	Until 10	11 to 50	51 to 100	101 to 500	over 500
		X			

2 - Number of associate members per tranche	Until 10	11 to 50	51 to 100	101 to 500	over 500
	X				

2°) Funding volume of other entities	0% to 10%	>10% to 50%	>50%
	X		

3°) Percentage of activities performed in Luxembourg	0% to 10%	>10% to 50%	>50%
			X

4°) Percentage of activities performed in the EU & EEA countries	0% to 10%	>10% to 50%	>50%
		X	

5°) Percentage of activities performed outside the EU & EEA countries	0% to 10%	>10% to 50%	>50%
	X		

6°) Funds transfer to EU & EEA countries	0% to 10%	>10% to 50%	>50%
		X	

7°) Funds transfer outside EU & EEA countries	0% to 10%	>10% to 50%	>50%
	X		

Breakdown of income

Funding source	Core funding received (2025)	As % of AE core income (2025)	Project funding received (2025)	As % of AE Project income (2025)	Total funding received (2025)	As % of AE total income (2025)	As % of AE total income (2024)
Roche			93,920	3.91%	93,920	2.99%	1.84%
Lilly			90,000	3.74%	90,000	2.86%	2.56%
Bristol Myers Squibb			46,000	1.91%	46,000	1.46%	0.96%
Biogen			37,500	1.56%	37,500	1.19%	0.88%
Novo Nordisk			35,000	1.46%	35,000	1.11%	1.28%
Eisai			35,000	1.46%	35,000	1.11%	0.80%
Johnson & Johnson			25,725	1.07%	25,725	0.82%	0.73%
Anavex			16,900	0.70%	16,900	0.54%	
UCB			16,720	0.70%	16,720	0.53%	
Merck Sharp & Dohme			10,000	0.42%	10,000	0.32%	0.24%
BioArctic			10,000	0.42%	10,000	0.32%	0.24%
Prothena							0.64%
Terumo BCT							0.61%
Otsuka							0.48%
Alzheon							0.32%
GlaxoSmithKline							0.01%
Sub-total Pharmaceutical funding			416,765	17.34%	416,765	13.26%	11.59%
C2N Diagnostics			27,500	1.14%	27,500	0.88%	0.72%
GE Healthcare			12,500	0.52%	12,500	0.40%	0.40%
Nutricia			12,500	0.52%	12,500	0.40%	0.40%
Evidera			1,100	0.05%	1,100	0.04%	0.21%
Essity							0.32%
Newsweaver							0.15%
Fujirebio							0.08%
CRA International UK							0.04%
Sub-total: Other corporate sources		0.00%	53,600	2.23%	53,600	1.71%	2.32%
Total Corporate funding		0.00%	470,365	19.57%	470,365	14.97%	13.91%
European Commission	566,860	76.74%	762,757	31.73%	1,329,617	42.31%	36.29%
Luxembourg National Research Fund (FNR)			154,371	6.42%	154,371	4.91%	6.15%
ADEM Luxembourg			30,260	1.26%	30,260	0.96%	
City of Bologna and Emilia Romagna Region			17,512	0.73%	17,512	0.56%	
Faillte Ireland			1,606	0.07%	1,606	0.05%	
Gesundheit Österreich			660	0.03%	660	0.02%	
Geneva City and Geneva Conference Centre							7.88%
Total: Public funding	566,860	76.74%	967,166	40.24%	1,534,026	48.82%	50.32%

BREAKDOWN OF INCOME

Funding source	Core funding received (2025)	As % of AE core income (2025)	Project funding received (2025)	As % of AE Project income (2025)	Total funding received (2025)	As % of AE total income (2025)	As % of AE total income (2024)
Gates Ventures			223,322	9.29%	223,322	7.11%	5.79%
Time donated by experts			120,450	5.01%	120,450	3.83%	4.14%
Deferred income			55,033	2.29%	55,033	1.75%	3.63%
Fondation Alzheimer, Luxembourg	87,000	11.78%			87,000	2.77%	2.78%
Alzheimer Europe Foundation			36,671	1.53%	36,671	1.17%	2.04%
Charité Berlin - TEF Health			34,000	1.41%	34,000	1.08%	1.09%
Fondation Médéric Alzheimer			25,000	1.04%	25,000	0.80%	0.17%
Fundació Catalunya La Pedrera			10,000	0.42%	10,000	0.32%	
Emeis			9,000	0.37%	9,000	0.29%	0.27%
INSERM			9,000	0.37%	9,000	0.29%	
Homedem			5,750	0.24%	5,750	0.18%	0.55%
Dublin College University - INTEREST			5,000	0.21%	5,000	0.16%	0.32%
La Meridiana			5,000	0.21%	5,000	0.16%	
Combidiag			5,000	0.21%	5,000	0.16%	
Radboud UMC			5,000	0.21%	5,000	0.16%	
Frontiers Media			4,500	0.19%	4,500	0.14%	
TClock4AD			4,000	0.17%	4,000	0.13%	
National Institute of Mental Health, Czechia			2,500	0.10%	2,500	0.08%	
Various organisations			1,468	0.06%	1,468	0.05%	0.17%
REBALANCE			1,250	0.05%	1,250	0.04%	0.20%
Vrije Universiteit Brussel			500	0.02%	500	0.02%	
CESAS			436	0.02%	436	0.01%	
University of Vechta			80	0.00%	80	0.00%	0.00%
GN Hearing							1.60%
EFPIA							1.60%
Nesta							0.36%
DZNE - PanEUCare							0.31%
Danish Dementia Research Centre-TIMING							0.10%
University of Bonn							0.10%
Concenctris - PRIME							0.10%
KU Leuven							0.10%
Storz Medical							0.07%
Fourtold							0.04%
Income received on account			-160,115	-6.66%	-160,115	-5.10%	-1.48%
Total: Foundations and organisations	87,000	11.78%	402,845	16.76%	489,845	15.59%	24.05%
Individuals (conference fees, donations, publication sales)	9,659	1.31%	553,300	23.02%	562,959	17.92%	8.71%
Total: Individuals	9,659	1.31%	553,300	23.02%	562,959	17.92%	8.71%
AE member organisations	72,160	9.77%	10,000	0.42%	82,160	2.61%	2.48%
Total: Member organisations	72,160	9.77%	10,000	0.42%	82,160	2.61%	2.48%
Bank interest and similar	2,961	0.40%			2,961	0.09%	0.53%
Total: Bank interest and similar	2,961	0.40%			2,961	0.09%	0.53%
Total Income	738,640	100.00%	2,403,676	100.00%	3,142,316	100.00%	100.00%

Our sponsors and supporters



Alzheimer Europe Board and staff

Alzheimer Europe Board members in 2025



Maria do Rosário
Zincke dos Reis
Chairperson
(Portugal)



Mario Possenti
Vice-Chairperson
(Italy)



Lorène Gilly
Honorary Secretary
(France)



Marco Blom
Honorary Treasurer
(Netherlands)



Kevin Quaid
Chairperson, EWGPWD



Trevor Salomon
Chairperson, EDCWG



Stefanie Becker
(Switzerland)



René Friederici
(Luxembourg)



Andy Heffernan
(Ireland)



Martina Mátlová
(Czechia)



Mary-Frances Morris
(Scotland, United Kingdom)



Katariina Suonu
(Finland)



René Thyrian
(Germany)

Alzheimer Europe staff members in 2025



Jean Georges
Executive Director



Angela Bradshaw
Director for Research



Dianne Gove
Director for Public Involvement and Ethics



Ana Diaz
Public Involvement Lead



Christophe Bintener
Project Officer



Cindy Birck
Project Officer



Kate Boor Ellis
Communications Officer



Sarah Campill
Public Involvement Officer



Isabelle Collot
Conference Coordinator
(From April 2025)



Lukas Duffner
Project Officer



Karim Elnaggar
Administrative Assistant
(From May to October 2025)



Faye Forsyth
Public Involvement Officer
(from September 2025)



Gwladys Guillory
Conference Coordinator
(Until January 2025)



Tara Klassen
Administrative Assistant
(During January and October to December 2025)



Sebastien Libert
Public Involvement Officer
(Until July 2025)



Owen Miller
Policy Officer



Soraya Moradi-Bachiller
Public Involvement Officer



Cristina Pencea
Events Coordinator



Stefanie Peulen
Finance Officer
(Until July 2025)



Margarita Reyes
Communications Officer
(From April 2025)



Fiona Sligo-Young
Finance Officer
(From May to October 2025)



Grazia Tomasini
Communications Assistant



**Co-funded by
the European Union**

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Commission. Neither the European Union nor the granting authority can be held responsible for them.



Alzheimer Europe a.s.b.l. • 5, Heienhaff • L-1736 Senningerberg • Luxembourg
R.C.S. LUXEMBOURG F2773 • EU TRANSPARENCY REGISTER NUMBER: 37399753690-65
Tel.: +352-29 79 70 • Fax: +352-29 79 72 • info@alzheimer-europe.org
Website: www.alzheimer-europe.org



[@alzheimer.europe](https://www.facebook.com/alzheimer.europe)



[@alzheimer-europe.bsky.social](https://bsky.app/profile/alzheimer-europe)



[alzheimer-europe](https://www.linkedin.com/company/alzheimer-europe)



[alzheimer-europe](https://www.instagram.com/alzheimer-europe)

ISBN 978-2-919835-09-6